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Alla mia famiglia—To my family 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This is a corner of a larger field… 
 
“Nothing in life is to be feared, it is only to be understood.  
Now is the time to understand more, so that we may fear less.” 
Marie Curie 
 

  
ABSTRACT 
The impact of prediabetes and diabetes on different stages of cognitive function during aging 
remains unclear. This thesis aimed to investigate the impact of prediabetes and of diabetes on 
cognitive aging—from cognitive deficits, through cognitive decline, to dementia—, explore 
underlying cerebral mechanisms and identify factors that may protect older adults with 
diabetes from dementia. The four studies in this thesis were based on data from the Swedish 
National Study on Aging and Care-Kungsholmen (SNAC-K), the SNAC-K brain magnetic 
resonance imaging (MRI) study, and the Swedish Adoption/Twin Study of Aging (SATSA). 
Study I. This study used SNAC-K data to identify the cognitive domains sensitive to the 
detrimental impact of diabetes. In cognitively intact older adults, diabetes was associated with 
lower performance in perceptual speed (β -1.10; 95% CI -1.98, -0.23), category fluency  
(β -1.27; 95% CI -2.52, -0.03), and digit span forward (β -0.35; 95% CI -0.54, -0.17). These 
results suggest that domains of fluid abilities are more sensitive to diabetes than are other 
cognitive domains. 
Study II. This study used 23 years of follow-up data from SATSA to investigate the effect of 
prediabetes and of diabetes on trajectories of cognitive decline in different domains. Diabetes 
accelerated cognitive decline in perceptual speed (β -0.25; 95% CI -0.44, -0.05) and verbal 
abilities (β -0.19; 95% CI -0.33, -0.04). Prediabetes was associated with poor memory 
performance at baseline but with a less steep memory decline over time. 
Study III. The relationship of prediabetes and of diabetes with global cognitive decline and 
structural brain changes was assessed with data from SNAC-K and the SNAC-K MRI study. 
Both accelerated global cognitive decline. Prediabetes was associated with smaller global 
brain volume, particularly smaller white matter volume at baseline, and diabetes with 
accumulation of white matter hyperintensities (β 0.56, 95% CI 0.07–1.05) over time.  
Study IV. The compensatory effect of an active and socially integrated lifestyle on dementia 
risk in older adults with diabetes was examined with data from SNAC-K. Participants with 
diabetes and an inactive lifestyle had a higher risk of dementia (HR 6.0, 95% CI 3.0–12.3) 
than diabetes-free participants with an active lifestyle (high engagement in leisure activities 
or/and rich social network). In participants with diabetes, an active lifestyle was associated 
with less of a raised risk (HR 1.9, 95% CI 1.1–3.4). 
Conclusions. In the initial phase of cognitive deterioration, the domains primarily affected by 
diabetes may be processing speed, executive function, and attention/primary memory. Over 
time, having either prediabetes or diabetes accelerates the decline in fluid abilities (i.e., 
perceptual speed and verbal abilities) and global cognitive decline. At the structural brain 
level, diabetes is associated with the accumulation of cerebral microvascular lesions, which 
might start already during prediabetes. Finally, diabetes is associated with an increased risk of 
dementia. However, an active and socially integrated lifestyle may significantly counteract 
the detrimental effect of diabetes on brain aging. 
Key words: prediabetes, type 2 diabetes, cognitive domains, cognitive decline, dementia, 
neuroimaging, white matter hyperintensities, cohort study, active lifestyle   
SAMMANFATTNING 
Påverkan av diabetes och prediabetes på olika stadier av kognitivt fungerande under 
åldrandeprocessen är ännu inte klarlagt. Syftet med denna avhandling var att undersöka hur 
diabetes och prediabetes påverkar kognitiv svikt, från begynnande kognitiv försämring till 
demens i en åldrande befolkning. Utöver det undersöks de underliggande hjärnmekanismerna 
och möjliga kompensatoriska faktorer mot demens för individer med diabetes. Avhandlingen 
innehåller fyra separata studier som använder data från ”the Swedish National Study on 
Aging and Care-Kungsholmen” (SNAC-K), ”SNAC-K brain magnetic resonance imaging” 
(MRI) studien, och ”the Swedish Adoption/Twin Study of Aging” (SATSA). De viktigaste 
resultaten är: 
Studie I. Vi identifierade samband mellan diabetes och olika kognitiva domäner med hjälp av 
data från SNAC-K. Bland de med normal kognitiv förmåga fann vi samband mellan diabetes 
och lägre perceptuell snabbhet (β -1.10; 95% CI -1.98, -0.23), verbalt flöde (β -1.27; 95% CI 
-2.52, -0.03), och uppmärksamhet (β -0.35; 95% CI -0.54, -0.17). Resultaten tyder på att 
diabetes påverkar flytande kognitiva förmågor tidigare än andra domäner.  
Studie II. Med hjälp av SATSA undersökte vi effekten av diabetes och prediabetes på den 
kognitiva försämringstakten i olika kognitiva domäner under 23 år. Diabetes ökade den 
kognitiva försämringstakten inom perceptuell snabbhet (β -0.25; 95% CI -0.44, -0.05) och 
verbala förmågor (β -0.19; 95% CI -0.33, -0.04). Prediabetes hade ett samband med sämre 
minne vid första undersökningstillfället men också med en långsammare försämring av 
minnesförmåga över tid. 
Studie III. Sambandet mellan diabetes, prediabetes och kognitiv försämringstakt samt 
strukturella hjärnförändringar undersöktes i SNAC-K och SNAC-K MRI. Prediabetes och 
diabetes påskyndade den kognitiva försämringen. Prediabetes hade ett samband med mindre 
hjärnvolym, speciellt den vita hjärnsubstansen, vid första undersökningstillfället. Diabetes var 
kopplat till ackumulation av vitsubstansskador över tid (β 0.56, 95% CI 0.07–1.05).  
Studie IV. Med data från SNAC-K undersöktes positiva effekter av en aktiv (t.ex. högt 
deltagande i fritidsaktiviteter) och social livsstil (t.ex. ett stort nätverk) på sambandet mellan 
diabetes och demens. Personer med diabetes och en inaktiv livsstil hade högre risk för 
demens än personer fria från diabetes med en aktiv livsstil (HR 6.0, 95% CI 3.0–12.3). 
Personer med diabetes med en aktiv livsstil hade inte en lika stor risk för demens (HR 1.9, 
95% CI 1.1–3.4)     
Sammanfattning. Perceptuell snabbhet, exekutiv förmåga och uppmärksamhet kan vara de 
första domänerna som påverkas av diabetes under den kognitiva försämringen. Prediabetes 
och diabetes kan påverka flytande kognitiva förmågor (tex perceptuell snabbhet och verbalt 
flöde) och globala kognition negativt över tid. Diabetes, och eventuellt även prediabetes, har 
ett samband med ökat antal mikrovaskulära skador i hjärnan. Avslutningsvis ökar diabetes 
risken för demens men en aktiv och social livsstil kan motverka de negativa effekterna av 
diabetes på hjärnans åldrande. 
Nyckelord: prediabetes; typ 2 diabetes; kognitiva domäner; kognitiv försämringstakt; 
demens; hjärnavbildning; vitsubstansskador; kohortstudie; aktiv livsstil.   
  
RIASSUNTO 
L’impatto del diabete e prediabete sulle diverse fasi del funzionamento cognitivo durante 
l’invecchiamento rimane poco chiaro. Questa tesi ha indagato l'impatto del prediabete e del 
diabete sull'invecchiamento cognitivo—dai deficit cognitivi, attaverso il declino cognitivo, fino 
alla demenza—esplorandone i meccanismi cerebrali, e ha identificato i fattori che potrebbero 
proteggere gli anziani con diabete dalla demenza. I quattro studi presentati in questa tesi 
utilizzano dati dai seguenti database: Swedish National Study on Aging and Care-Kungsholmen 
(SNAC-K), SNAC-K brain magnetic resonance imaging (MRI) e Swedish Adoption/Twin 
Study of Aging (SATSA). 
Studio I. Questo studio ha utilizzato i dati di SNAC-K per identificare i domini cognitivi piú 
sensibili all’impatto dannoso del diabete. Negli anziani cognitivamente intatti, il diabete é 
associato a minore velocità psicomotoria (β -1.10; 95% CI -1.98, -0.23) e scarse performance 
nella fluenza verbale per categorie (β -1.27; 95% CI -2.52, -0.03) e nello span di cifre in avanti 
(β -0.35; 95% CI -0.54, -0.17). Questi risultati suggeriscono che i domini delle abilità fluide 
sono piú sensibili ai danni legati al diabete rispetto agli altri domini cognitivi.  
Studio II. Questo studio ha utilizzato i dati di 23 anni di follow-up di SATSA per investigare 
l’effetto del prediabete e diabete sulle traiettorie di declino cognitivo in diversi domini. Il 
diabete é associato a un maggiore declino nella velocità psicomotoria (β -0.25; 95% CI -0.44, -
0.05) e nelle abilità verbali (β -0.19; 95% CI -0.33, -0.04). Il prediabete é associato a scarse 
prestazioni di memoria al basale, ma con minore declino mnestico nel tempo. 
Studio III. La relazione tra prediabete, diabete, declino cognitivo globale e cambiamenti 
cerebrali strutturali é stata valutata utilizzando dati di SNAC-K e SNAC-K MRI. Prediabete e 
diabete mostrano un declino cognitivo globale accellerato. Durante il follow-up, il prediabete é 
associato con minore volume cerebrale, in particolare della sostanza bianca, mentre il diabete é 
associato con un accumulo piú  veloce di iperintensità della sostanza bianca cerebrale. 
Studio IV. L'effetto compensatorio di uno stile di vita attivo e socialmente integrato sul rischio 
di demenza nel diabete è stato esaminato usando i dati di SNAC-K. I partecipanti con diabete e 
stile di vita inattivo hanno un aumentato rischio di demenza (HR 6.0, 95% CI 3.0-12.3) rispetto 
agli anziani non-diabetici con stile di vita attivo (elevato coinvolgimento in attività ricreative e/o 
ricca rete sociale). Nei partecipanti con diabete, uno stile di vita attivo é associato a un minor 
rischio di demenza (HR 1.9, IC 95% 1.1-3.4). 
Conclusione. Nella fase iniziale del deterioramento cognitivo, i domini primariamente 
danneggiati dal diabete sono velocità psicomotoria, le funzioni esecutive, e attenzione/memoria 
primaria. Le persone con prediabete o il diabete hanno un accellerato declino cognitivo delle 
abilità fluide (ad esempio, la velocità psicomotoria e le abilità verbali) e declino cognitivo 
globale. A livello cerebrale, il diabete si associa ad un accumulo di lesioni cerebrali 
microvascolari, che potrebbero iniziare già durante la fase prediabetica. Infine, il diabete 
aumenta il rischio di demenza. Tuttavia, uno stile di vita attivo e socialmente integrato può 
contrastare in modo significativo l'effetto dannoso del diabete sull'invecchiamento cerebrale. 
Parole chiave: prediabete; diabete di tipo 2; domini cognitivi; declino cognitivo; demenza; 
neuroimmagine; iperintensità della sostanza bianca; studio di coorte; stile di vita attivo.  
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1 INTRODUCTION  
1.1 AGING—THE BURDEN OF DIABETES AND DEMENTIA 
Decreasing mortality in people of all ages has contributed to an increase in life expectancy, 
which is a key driver of the world's rapidly growing aging population (1). Increasing life 
expectancy is a success story, as it reflects better living conditions, and especially after the 
50s, improved health care and public health. However, with increasing age, several 
pathological changes occur in the body, affecting all organs. Consequently, as the population 
ages, a substantial increase in numbers of chronic and neurodegenerative disorders, such as 
dementia, is expected. 
Dementia is a syndrome caused by a range of neurological conditions and characterized by 
progressive functional impairment of mental processes (also known as cognitive domains), 
such as memory, attention, speed of processing information, executive function, reasoning, 
visuospatial abilities, and language (2, 3). Dementia is a huge burden for patients, their 
families, and society, as by definition, the cognitive deficits interfere with daily personal, 
social, and professional life. Dementia’s consequences are devastating both at the individual 
and societal level (3). In 2015, almost 47 million people aged ≥60 years, a number that 
corresponds to 5% to 7% of the worldwide population, had dementia; these numbers are 
expected to nearly triple in the next 30 years (3, 4). Alzheimer’s disease (AD) is the most 
common cause of dementia in older adults, accounting for 50% to 70% of cases. Next most 
common are vascular dementia (VaD) and mixed dementia (3). Dementia begins several 
years before its clinical diagnosis (5), and several studies suggest that cognitive deficits in 
different domains can be detected nearly a decade before the diagnosis (6). Type 2 diabetes 
(hereafter, diabetes) has been identified as one of the major risk factor for dementia, 
conferring about double the risk (7, 8). A 2014 study estimated that almost 3% of dementia 
cases can be attributed to diabetes (9).  
Briefly, diabetes is a chronic metabolic condition characterized by increased levels of glucose 
in the blood, i.e. hyperglycemia. It occurs when the pancreas cannot produce any or enough 
insulin or the body cannot effectively use the produced insulin (10). Diabetes is one of the 
leading causes of cardio- and cerebrovascular disorders, retinopathy, disability, and death and 
it imposes a significant economic burden on healthcare systems (11). According to the latest 
report from the International Diabetes Federation, in 2017, there were 123 million people 
aged 65 years or older living with diabetes in the world (9.6% of the population older than 65 
years), including 29 million in Europe (11). Prediabetes is a highly heterogeneous metabolic 
state characterized by hyperglycemia, but at concentration below that required for diabetes 
diagnosis. It usually precedes diabetes. Overall, prediabetes affects 352 million adults in the 
world (7.3% of the adult population), and up to 10% of prediabetes cases will progress to 
diabetes every year (12). 
Diabetes and dementia have emerged as major global health issues and burdens in people 
older than 60 years. Both the aging global population and less healthy lifestyles are 
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contributing to the rapid increase in the numbers of older people with diabetes and/or 
dementia. The numbers of older people with diabetes or dementia are foreseen to rise 
substantially in the next three decades—from 123 million to 253 million for diabetes, and 
from 47 million to 132 million for dementia (4, 11). Currently, there is no pharmacological 
treatment to cure dementia, and preventative strategies that target potential causes or 
mediators are still under debate. With this in mind, diabetes and prediabetes should be 
regarded as important targets for the prevention of dementia syndromes (8).  
 
1.2 PREDIABETES, DIABETES, AND COGNITIVE AGING  
Cognitive aging has been defined as the “lifelong process of gradual, ongoing, yet highly 
variable changes in cognitive function that occurs when people get older” (13). Age-related 
physiological changes also affect the brain, both its physical structures and its ability to 
execute various functions (i.e., cognitive function). Therefore, as people age, their cognitive 
function gradually starts to decline. The decline shows great inter- and intra-individual 
variability across different domains (e.g., memory, attention, processing speed, and executive 
function) (13). People need preserved cognition to function well in daily life (e.g., solve 
problems, manage finances, handle medications, and keep house), perform basic activities of 
daily living (such as feeding, dressing, and toileting), engage in an active lifestyle, maintain 
social interactions, and therefore age successfully. The brain-computer metaphor (illustrated in 
detail in Figure 1) can be used to better understand how brain and cognition are related to 
functioning in everyday life (2). In brief, the sensory organs’ receptors receive environmental 
information (analogous to a computer receiving input), which is transduced to an action 
potential and conducted to specific brain areas where the stimuli are actively processed. The 
perceived information can either be consolidated and stored in long-term memory for future 
retrieval or temporarily stored in short-term memory and carried into other brain areas related 
to specific cognitive domains where the information is further reorganized and processed 
(analogous to a computer's processing phase). The elaborated information is, finally, retrieved 
and conveyed to a specific system (such as the motor cortex) that will produce a behavioral 
response (analogous to a computer's output) (2). 
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Figure 1. The relationship between brain receptive functions, brain cognitive processes, and 
daily life behaviors is analogous to the relationship between computer input, processing, and 
output. 
 
However, as people age, multiple health-related conditions such as cerebro- and 
cardiovascular disorders (CVDs), metabolic disorders, and neurodegenerative disorders can 
affect cognitive function, accelerating cognitive aging (14). Cognitive impairment is an 
intermediate stage between expected age-related cognitive changes and disease-related 
cognitive changes and as such will likely evolve to dementia over time (15). Identifying 
cognitive profiles associated with age-related health conditions (i.e., prediabetes or diabetes) 
is important because such profiles can improve our understanding of 1) the nature of the 
association between the specific health condition and the related cognitive decline and 2) the 
underlying biological mechanisms, thereby helping prevent cognitive impairment and 
dementia in old age. 
 
1.2.1 Prediabetes, diabetes, and deficits in cognitive domains 
As early as the 1920s, researchers recognized that diabetes may affect cognitive function 
(16). Since then, numerous studies have examined the association between diabetes and 
cognitive function. We identified 30 cross-sectional or case-control studies that have 
addressed this topic in the last two decades; the methods and findings of these studies are 
summarized in Appendix 11.1. These studies consistently showed that older people with 
diabetes have modestly worse cognition than those who are diabetes-free. However, the 
cognitive domains affected by diabetes are less clear. The relationships between diabetes and 
the cognitive domains of memory (i.e., episodic, semantic, primary, and working memory), 
attention/executive function, and processing speed are the most studied, and results have been 
mixed. Twenty-five studies have examined the relationship between memory function and 
diabetes. Only nine studies reported significant associations between diabetes and poor 
memory performance (17-25), whereas the remaining studies found no association (26-41). 
Attention/executive function was considered in 20 studies, of which 13 reported significantly 
lower performance in people who had diabetes than those who did not (17, 21, 23, 27-33, 38, 
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41, 42). An association between deficits in processing speed and diabetes has been observed 
in some studies (17, 21-23, 29, 31-33, 36, 42), but not in others (18, 19, 25, 34, 40). 
Visuospatial and language domains have been less explored, and findings on their association 
with diabetes differed. Two out of the eight studies found lower performance on visuospatial 
tasks that require spatial and constructional skills in people with diabetes than in people 
without the disease (23, 28). Similarly, of the 10 studies that examined verbal fluency, only 
two reported poorer performance in people with diabetes than people without diabetes (24, 
38). Few studies have examined the relationship between prediabetes and cognitive deficits, 
and they reported no association (17, 27, 31, 36, 39). Altogether, these findings suggest that 
memory, executive function, and speed might be impaired in people with diabetes, but not in 
those with prediabetes.  
Discrepancies among these studies may reflect methodological differences in the number and 
characteristics of study participants and the assessments of both diabetes and cognitive 
domains. First, about half of these studies assessed diabetes based on self-report or use of 
antidiabetic medications without including any measures of blood glucose, and they did not 
consider prediabetes. Second, important confounders (e.g., age, education, comorbidities) and 
potential effect modifiers varied across the studies. Third, many studies included screening 
test for global cognition (i.e., the Mini-Mental State Examination or MMSE). This would 
increase ceiling and floor effects and not capture subtle cognitive deficits, particularly in 
speed and executive function. Moreover, most studies have used only one test to assess each 
cognitive domain that would increase the measurement error, thus increasing error variance. 
Fourth, participants with dementia (which was usually assessed via self-report), were 
excluded in only half of the studies and none of these previous studies took cognitive 
impairment into account. People with cognitive impairment or dementia were thus included, 
so the observed cognitive deficits may reflect underlying neurodegenerative pathology rather 
than a specific diabetes-related etiology. 
 
1.2.2 Prediabetes, diabetes, and cognitive decline 
We identified 28 longitudinal studies that examined the relationship between diabetes and 
cognitive decline (Appendix 11.2). Although some studies found accelerated cognitive 
decline in older people with diabetes (43, 44), others did not observe such an association (26, 
29, 33, 36, 45-47). Furthermore, findings on the cognitive domains affected by diabetes were 
inconsistent. Only five studies addressed the effect of prediabetes on the rate of cognitive 
decline (27, 36, 41, 48, 49); they reported no association. 
Fourteen studies included people aged ≥60 years; three of these included people ≥75 years 
(26, 33, 50), and 13 included participants ≥40 years. Follow-up varied between one and 20 
years; however, only six studies had relatively long follow-up periods (≥10 years) (27, 45, 
51-54). Additionally, the majority of the studies examined diabetes as predictor of cognitive 
decline without specifying the stage of cognitive aging that was of interest; i.e., overall 
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decline or decline prior to dementia. Consequently, the inclusion of cognitive impairment or 
incident dementia cases together with the wide age ranges might have led to reverse causation 
or systematic errors. The studies assessed cognitive domains differently. They most often 
used screening tools such as the MMSE or single cognitive tests to evaluate cognitive 
domains. Only nine studies have used composite measures derived from a battery of 
cognitive tests (12, 27, 29, 46, 49, 52, 55-57); of those, one study extracted the domains with 
factor analysis (58). The use of composite domain measures reduces the complexity of data 
and the likelihood of measurement errors (e.g., floor and ceiling effects) that distort estimates 
of change. Furthermore, error variance associated with specific cognitive tasks is minimized 
when composite domains are extracted by structural equation modeling or factorial analyses. 
Finally, in previous studies, the ascertainment of diabetes was heterogeneous. Diagnostic 
tests for diabetes such as oral glucose tolerance, glycated hemoglobin (HbA1c), random 
blood glucose (RBG), or fasting blood glucose (FBG) were used in half of the studies. The 
other half assessed diabetes via self-reported diabetes or self-reported use of glucose-
lowering medications, which can lead to misclassification and underdiagnosis of diabetes and 
prediabetes.  
 
1.2.3 Prediabetes, diabetes, and dementia 
Diabetes is a well-established risk factor for dementia. It confers an approximatively 60% 
increase in the risk of all-cause dementia, a 40% increase in the risk of non-vascular 
dementia, and up to 2.3-times higher risk of vascular dementia (8, 59). However, it is not 
clear whether prediabetes predicts dementia and studies addressing this question are relatively 
sparse. A study using data from the Kungsholmen project was the first to show that 
prediabetes was associated with a 70% increased risk of dementia (60). Since then, few 
prospective studies have explored the link between different markers of prediabetes—
impaired glucose tolerance (IGT), FBG, or insulin resistance—and dementia, and the results 
of the studies that have been done are controversial. Findings from a 15-year follow-up study 
in Sweden showed that women with impaired FBG had higher odds of dementia than women 
with normal blood glucose (61). However, another Swedish community-based study that 
included >70-year-old men reported no association between FBG or impaired glucose 
tolerance and dementia over 12 years of follow-up (62). Discrepancies in findings may reflect 
differences in the laboratory tests used to identify prediabetes and in the tests used to assess 
dementia, which were mostly screening tools, rather than clinical assessments. 
 
1.3 PREDIABETES, DIABETES, AND BRAIN AGING  
The biological bases that underpin the relationship between prediabetes or diabetes and 
cognitive aging are still unclear. Researchers have proposed that the pathogenesis is 
multifactorial, involving a complex interplay between systemic, biochemical, and cerebral 
mechanisms (63-65) (Figure 2).  
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Brain atrophy is the most investigated cerebral marker of diabetes-related cognitive decline 
and dementia (5). It is characterized by widened sulci, narrowed gyri, thinning of the cortical 
mantle, and consequent reduction of brain tissue size (so-called shrinkage) due to the 
progressive loss of neurons and their connections (2). As aging advances, the brain slowly 
undergoes some modifications, and neuronal loss occurs naturally as a defensive mechanism 
when cells are damaged (2). However, neurodegenerative diseases are characterized by 
excessive apoptosis and subsequent progressive brain atrophy (5, 66). Metabolic conditions 
and hyperglycemia affect the vascular system by accelerating atherosclerotic processes in the 
brain, results in brain abnormalities such as white matter loss and brain atrophy (2, 67, 68). 
The medial temporal lobe contains structures, such as the hippocampus and adjacent regions, 
that are essential for episodic memory and long-term memory (69). Medial temporal lobe 
atrophy is a core feature of typical AD (70). On the other hand, small vessels disease (SVD), 
including brain atrophy and white matter hyperintensities (WMH), are the major contributors 
to vascular dementia (71). Currently, two plausible pathways have been hypothesized to 
explain the association between diabetes and accelerated cognitive decline/dementia: 1) AD-
related neurodegeneration (i.e., medial temporal lobe atrophy [including hippocampal 
atrophy]), and 2) cerebrovascular-related lesions (65).  
 
 
Figure 2. Multifactorial pathways underlying cognitive dysfunction and dementia in people 
with diabetes. 
The biological mechanisms of prediabetes- and diabetes-related cognitive dysfunction or dementia 
rely on a complex interplay between several mechanisms that probably stem from hyperglycemia. 
Cardiovascular diseases, chronic inflammation, high glucose levels, and advanced glycoxidation end-
products (AGEs) can accelerate atherosclerotic processes in the brain, resulting in brain 
abnormalities; that is, atrophy and small vessel diseases (SVD), including white matter 
hyperintensities (WMH). These brain abnormalities may accelerate cognitive decline and, over time, 
lead to dementia.   
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In the last twenty years, brain-imaging techniques have greatly advanced our clinical and 
scientific understanding of the etiology of different dementia syndromes. Magnetic resonance 
imaging (MRI) is an excellent technique at detecting structural brain markers of AD- or 
cerebrovascular-related degeneration (72, 73). Previous cross-sectional studies have 
consistently shown associations between diabetes and smaller total brain volume (63, 74-79). 
We identified only six longitudinal studies from the last 20 years that have used structural 
MRI to address the effects of diabetes on brain atrophy (Appendix 11.3) (80-85). Some 
reported faster rates of brain volume loss, especially in the lateral ventricles, in people with 
diabetes than in those without the disease (80-82, 85). However, other studies did not find 
differences in the rate of brain volume loss between people with and without diabetes (83, 
84). These longitudinal studies differ in the methods used to measure brain atrophy 
(thickness-based vs. volume-based) and the markers of brain atrophy itself (e.g., total brain 
tissue and gray matter, white matter, and ventricular volumes), which could explain the 
heterogeneous results. 
Recently, there has been increasing interest in understanding the extent to which SVD 
contribute to diabetes-related cognitive dysfunction and dementia. SVD are a group of 
pathological processes with various etiologies that affect the small arteries, arterioles, 
venules, and capillaries of the brain (86). During aging, SVD are one of the major 
contributors to vascular cognitive impairment and dementia (71). Signs of SVD include small 
subcortical infarcts, lacunes, microbleeds, perivascular spaces, brain atrophy, and WMH (71). 
WMH are patchy or confluent hyperintensities in the white matter detected on the MRI that 
are linked to demyelination and axonal destruction (i.e., extensities WMH) or microglia and 
endothelial activation (i.e., subtle WMH) (87, 88). Diabetes has been associated with higher 
burden of SVD (63). In particular, its association with WMH has been investigated in several 
studies, but results are inconsistent. A few cross-sectional studies found greater WMH 
volume or more white matter lesions in older adults with diabetes than in those without 
diabetes (74, 76, 89), but most reported no differences (77, 79, 90, 91). To our knowledge, 
only four longitudinal studies have examined whether diabetes is related to WMH changes; 
they report no differences in the rates of change between people with and without diabetes 
(81-83, 85). 
Because of the established association between diabetes and AD, numerous researchers have 
investigated whether diabetes is associated with structural abnormalities in the hippocampus; 
results are mixed. Only two cross-sectional studies found that lower hippocampal volumes 
were related to diabetes (77, 79), whereas longitudinal studies found no associations (63, 83).  
Finally, three cross-sectional (74, 76, 89) and two longitudinal (80, 83) population-based 
studies examined the relationship between prediabetes and structural brain MRI markers. 
They reported mixed results. 
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1.4 KNOWLEDGE GAPS 
Taken together, the findings of previous studies highlight important gaps in knowledge 
regarding prediabetes or diabetes and cognitive aging. 
First, the initial phases of cognitive deterioration related to diabetes remain insufficiently 
explored, and the cognitive domains affected early by diabetes have not yet been 
characterized. Second, whether diabetes and especially prediabetes are associated with 
cognitive decline remains unclear. Third, the biological mechanisms underlying cognitive 
decline in diabetes remain unclear. In particular, it is not clear whether cognitive dysfunction 
is linked to vascular or AD-related neurodegenerative mechanisms. Furthermore, we do not 
know whether already prediabetes affects the brain, and there is a lack of population-based 
MRI studies on the association between prediabetes and brain markers of AD-related or 
vascular degeneration. Similarly, although the relationship between diabetes and dementia is 
well established, much less is known about the association between prediabetes and increased 
risk of dementia. 
Finally, numerous studies have tried to understand the individual risk factors that can predict 
an increased risk of diabetes or an increased risk of dementia. However, none has tried to 
understand which protective modifiable lifestyle behaviors can protect people with diabetes 
from dementia. Indeed, as dementia and diabetes share similar risk factors, mostly related to 
lifestyle behaviors (92, 93), it seems reasonable to hypothesize that an active lifestyle could 
lower the risk of dementia in people with diabetes. 
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1.5 RESEARCH HYPOTHESIS 
This thesis tested the hypothesis that prediabetes and diabetes affect different phases of 
cognitive aging. In cognitive aging, a person can move from being cognitively intact, to 
experiencing the onset of slight cognitive deficits, through cognitive decline, to dementia.  
An underlying assumption in the thesis was that high blood glucose (i.e., hyperglycemia), 
CVDs, vascular risk factors (VRF), and APOE ɛ4 may modulate the relationship between 
prediabetes or diabetes and accelerated cognitive aging. A second underlying assumption was 
that brain markers such as atrophy and microvascular lesions could explain this relationship. 
A third was that other modifiable factors, such as an active lifestyle, could help slow 
prediabetes- or diabetes-related cognitive aging (Figure 3). 
 
 
 
Figure 3. Schematic representation of the research hypothesis. 
Abbreviations: APOE ɛ4, apolipoprotein E gene-ɛ4 allele; CVDs, cardio- and cerebrovascular 
disorders; VRF, vascular risk factors. 
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2 AIMS 
 
2.1 GENERAL AIM 
This thesis investigated the impact of prediabetes and diabetes on different phases of 
cognitive aging (from being cognitively intact, through experiencing cognitive decline, to 
dementia), exploring the cerebral mechanisms that underlie the impact of prediabetes and 
diabetes on cognitive decline and attempting to identify factors that may protect people with 
diabetes from dementia. 
 
2.2 SPECIFIC AIMS 
The specific aims addressed in four studies were: 
1. To identify which cognitive domains are impaired early by prediabetes and diabetes 
and, to explore whether glycemic control, VRFs, CVDs, and APOE ɛ4 modulate the 
association between prediabetes or diabetes and cognitive function (Study I). 
 
2. To examine the long-term effect of prediabetes and diabetes on trajectories of 
cognitive decline in different domains prior to the diagnosis of dementia (Study II). 
 
3. To investigate the impact of prediabetes and diabetes on global cognitive decline and 
brain structural changes (Study III). 
 
4. To estimate the relationship between prediabetes and dementia and diabetes and 
dementia, and to explore whether an active lifestyle could counteract the risk effect of 
prediabetes or diabetes on dementia (Study IV). 
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3 MATERIALS AND METHODS 
This PhD project is based on data from the Swedish National Study on Aging and Care-
Kungsholmen (SNAC-K), the SNAC-K brain MRI study (SNAC-K MRI), and the Swedish 
Adoption/Twin Study of Aging (SATSA). 
3.1 POPULATION-BASED DATASETS 
3.1.1 The Swedish National Study on Aging and Care-Kungsholmen 
During March 2001 through June 2004, 4790 eligible people, aged ≥60 years, living either at 
home or in institutions in Kungsholmen (central Stockholm, Sweden) were invited to 
participate in the baseline assessment. The sampling was stratified by eleven specific age-
cohorts and assessment interval (i.e. three and six years) because of more rapid changes in 
health and a higher attrition rate in older age groups. The younger age cohorts (60, 66, and 72 
years) were followed every sixth year and the older age cohorts (78, 81, 84, 87, 90, 93, 96, 
and ≥99 years) every third year (Figure 4). Of the original 5111 people invited to participate, 
262 had no contact information, 200 died before the baseline assessment, and 59 were deaf, 
moved away, or were not Swedish speakers. Of the 4590 alive and eligible older adults, 1227 
declined to participate, leaving a study population of 3363 (73.3%).  
 
 
Figure 4. The Swedish National Study on Aging and Care-Kungsholmen (SNAC-K) study design 
The figure shows the SNAC-K assessment waves included in this thesis, from baseline (B) to the most 
recent follow-up for which data were available (F1=first follow-up, F2=second follow-up, F3=third 
follow-up). 
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Study populations. A schematic representation of the baseline populations and participants 
derived from SNAC-K and used in studies I, III, and IV is illustrated in Figure 5. In 
summary, Study I was cross-sectional and included 2305 cognitively intact participants who 
performed the cognitive test battery. Studies III (n=2746) and IV (n=2650), both longitudinal, 
followed dementia-free participants up to February 2013.       
Data collection. At each wave, following standard protocols (available at http://www.snac-
k.se/), physicians conducted clinical examinations and trained psychologists administered a 
comprehensive neuropsychological battery. Nurses collected data on sociodemographics, 
lifestyle factors, and medical history and measured anthropometrics and arterial parameters. 
Peripheral blood samples were taken from all participants.      
 
3.1.2 The Swedish National Study on Aging and Care-Kungsholmen MRI 
study  
During baseline (September 2001–October 2003), a subsample of 555 SNAC-K participants 
who did not live in an institution, were not disabled, and did not have dementia was randomly 
selected and invited to undergo a MRI examination. A total of 455 participants from the 
SNAC-K MRI study who did not have neurological or neuropsychiatric conditions were 
included in Study III (Figure 5). 
 
  
Figure 5. SNAC-K and SNAC-K MRI study populations in studies I, III, and IV. 
Abbreviations: CIND, cognitive impairment-no dementia; HbA1c, glycated hemoglobin; MRI, 
magnetic resonance imaging; SNAC-K, Swedish National Study on Aging and Care-
Kungsholmen; T1D, type 1 diabetes.  
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3.1.3  The Swedish Adoption/Twin Study of Aging study 
SATSA is a population-based longitudinal study consisting of a subset of twin pairs from the 
Swedish Twin Registry (94). The twins from the registry who were reared apart and a 
matched sample of those who were reared together were interviewed by mailed questionnaire 
in 1984. Of the twins who responded to the first questionnaire, those who were aged >50 or 
older were further invited to undergo clinical examinations and cognitive assessments starting 
in 1986 (first in-person testing, n=645). Between 1986 and 2010, participants were assessed 
approximately every third year by trained nurses. Throughout the study follow-up period, 
eight waves of examinations were carried out. Additionally, during the study period, when 
twins in SATSA turned 50 years old, they were invited to participate in the follow-up 
examination that was ongoing. Because of the open-cohort design, the date of each 
participant's entry into the study was considered that person's baseline date. A total of 862 
people participated in the baseline assessment and completed the cognitive protocol (Figure 
6). 
Study population. In Study II, participants with cognitive impairment-no dementia (CIND), 
dementia, and missing blood glucose concentration values were excluded, leaving a study 
population of 793 relatively cognitively intact participants at baseline (Figure 6).   
 
 
Figure 6. SATSA study design and population for Study II.  
The number in parentheses indicates those whose baseline was at each occasion after IPT1. The 
figure shows the waves of assessment in SATSA. The date at the participants’ study entry was 
considered as baseline (n=862 including n=645 at IPT1, n=93 at IPT2, n=21 at IPT3, n=99 at IPT5, 
n=1 at IPT6, and n=3 at IPT8).  
Abbreviations: CIND, cognitive impairment-no dementia; IPT, in-person testing; SATSA, Swedish 
Adoption/Twin Study of Aging. 
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Data collection. At each wave, information on demographics, lifestyle factors, medical 
conditions, current medications, and fasting status was collected through structured interview. 
Anthropometrics and arterial blood pressure were measured, and peripheral blood samples 
were taken from all participants. 
 
3.2 ASSESSMENT OF DIABETES STATUS  
In all datasets, diabetes status (diabetes, prediabetes, and glycemic control) was ascertained at 
baseline and follow-ups.  
In SNAC-K, until December 2010, glycated hemoglobin (HbA1c [%]) was measured using 
Swedish Mono-S High Performance Liquid Chromatography. In accordance with the 
National Glycohemoglobin Standardization Program (NGSP), 1.1% was added to the HbA1c 
value to make them equivalent to international values (95). Beginning in January 2011, 
HbA1c was standardized using the International Federation of Clinical Chemistry (IFCC)’s 
method (96). A standard equation (NGSP = [0.09148 * IFCC] + 2.152) 
(http://www.ngsp.org/ifccngsp.asp) was applied to convert from IFCC HbA1c (mmol/mol) to 
NGSP (%) (97).  
Diabetes and prediabetes. Diabetes was identified based on self-reported medical history, 
glucose-lowering medications, medical records from the Swedish National Patient Register 
(ICD-10 code E11), or HbA1c ≥6.5% (98). Prediabetes was defined as HbA1c of 5.7%–6.4% 
in diabetes-free participants (98). In Study III, HbA1c was divided into quintiles (Q1 to Q5), 
ranging from normoglycemia to hyperglycemia (Q4 to Q5 [HbA1c ≥5.8%]).  
In SATSA, information on fasting status and fasting hours was collected by nurses. If the 
participant had fasted for ≥8 hours, the measurement taken was considered to be FBG. 
Diabetes was ascertained based on self-reported medical history, glucose-lowering 
medications, or FBG ≥7.0 mmol/L (or non-fasting blood glucose ≥11 mmol/L). Prediabetes 
was defined as FBG 5.6–7.0 mmol/L (or non-fasting blood glucose 7.8–11.0 mmol/L) in 
diabetes-free participants.  
 
3.3 ASSESSMENT OF OUTCOMES  
3.3.1 Cognitive domains 
In all datasets, global cognitive function was measured with the MMSE. 
In SNAC-K, a battery of 10 cognitive tests (Table 1) was administered in a fixed order to 
assess the domains of perceptual speed, category fluency, letter fluency, semantic memory, 
and episodic memory. Cognitive domains were latent factors generated using structural 
equation modeling (99). In addition, the digit span forward and backward tests were 
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administered and participants' original score on these tests were used to assess 
attention/primary memory and working memory, respectively. 
In SATSA, the cognitive battery included 11 cognitive tests (Table 1) that assessed four 
specific domains: verbal abilities, spatial/fluid abilities, memory, and processing speed. These 
domains were identified by principal component analysis (100). 
 
Table 1. Cognitive assessment in SNAC-K and SATSA. 
Cognitive 
assessment SNAC-K  SATSA  
Cognitive domains             Perceptual speed: 
Digit cancellation  
Patterns comparison 
Category fluency: 
Animals 
Professions  
Letter fluency: 
Letter A 
Letter F 
Semantic memory: 
30-Multi-choice synonym test 
General knowledge  
Episodic memory:  
Word recall task 
Recognition task 
Attention/primary memory: 
Digit span forward 
Working memory:  
Digit span backwards  
Perceptual speed: 
Digit symbol  
Figure identification  
Memory 
Digit span forward 
Digit span backward 
Thurstone’s picture test 
Verbal abilities: 
Information test 
Synonyms (from WAIS) 
Analogies (from WAIS) 
Spatial/fluid abilities: 
Figure logic 
Kohs Block design  
Card rotation task  
 
Abbreviations: SATSA, Swedish Adoption/Twin Study of Aging; SNAC-K, Swedish National Study on 
Aging and Care- Kungsholmen; WAIS, Wechsler Adult Intelligence Scale. 
 
3.3.2 Cognitive impairment and dementia 
In SNAC-K and SATSA, CIND was defined as the presence of objective cognitive 
impairment in any domain in absence of dementia (101). Age- and education-specific 
cognitive norms were calculated in the dementia-free study participants. At baseline, 
participants were identified as having CIND if they were 50–75 years and scored ≥1 standard 
deviation (SD) below the age- and education-specific mean MMSE score or were ≥75 years 
and scored ≥2 SDs below the age- and education-specific mean (102, 103). In both studies, 
dementia was diagnosed according to the Diagnostic and Statistical Manual of Mental 
Disorders (3rd or 4th edition) revised criteria.  
In SNAC-K, all-cause dementia (hereafter, dementia) was diagnosed using a 3-step 
procedure. First, two examining physicians independently made preliminary diagnoses of 
dementia on the basis of the participant’s physical, neurological, and cognitive status (steps 
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one and two). In case of discrepancy between the two diagnoses, in step three, a senior 
neurologist was consulted to reach a concordant diagnosis. For participants who died during 
follow-up, one physician extracted the diagnosis of dementia and dementia subtypes by 
consulting the available death certificate or medical records at hospital discharge when 
available. Differential diagnoses of Alzheimer’s diseases (AD) was made in accordance with 
standard criteria in The National Institute of Neurological and Communicative Disorders and 
Stroke-Alzheimer’s Disease and Related Disorders Association, and differential diagnosis of 
vascular dementia (VaD) with the standard criteria in the Neuroepidemiology Branch of the 
National Institute of Neurological Disorders and Stroke-Association Internationale pour la 
Recherche et l'Enseignement en Neurosciences (104, 105). Mixed dementia was identified 
when participant had both features of AD and VaD.  
In SATSA, dementia was diagnosed during a consensus conference based on all available 
information from the nurse visit, medical records, and cognitive assessment (106).  
 
3.3.3 Brain MRI markers 
SNAC-K MRI Protocol. Participants were scanned with a 1.5T MRI scanner (Philips Intera, 
The Netherlands). The protocol included an axial 3D T1-weighted fast field echo (repetition 
time [TR] 15 ms, echo time [TE] 7 ms, flip angle [FA] 15°, field of view [FOV] 240, 128 
slices with slice thickness 1.5 mm and in-plane resolution 0.94 × 0.94 mm, no gap, matrix 
256 × 256), and an axial turbo fluid-attenuated inversion recovery sequence (FLAIR; TR 
6000 ms, TE 100 ms, inversion time 1900 ms, FA 90°, echo train length 21, FOV 230, 22 
slices with slice thickness 5 mm and in-plane resolution 0.90 × 0.90 mm, gap 1 mm, matrix 
256 × 256). 
Brain markers. The volumes of grey matter (GMV), white matter (WMV), and 
cerebrospinal fluid were derived after segmentation of the T1-weighted images in SPM12 
(Statistical Parametric Mapping, http://www.fil.ion.ucl.ac.uk/spm/, Wellcome Trust Centre 
for Neuroimaging, FIL, London, UK), implemented in Matlab 10 (The Mathworks Inc., MA, 
USA), using the improved unified segmentation algorithm that employs an extended set of 
tissue-probability maps (107). The “light cleanup” option was used to further remove odd 
voxels from the images. Total brain tissue volume (TBTV) was obtained by summing GMV 
and WMV. Hippocampal volume (HV) was computed with automated segmentation of the 
T1-weighted images performed with the Freesurfer 5.1 image-analysis suite 
(http://surfer.nmr.mgh.harvard.edu/) (108, 109). White matter hyperintensities volume 
(WMHV) was manually drawn on FLAIR images by a neuroimaging expert and further 
interpolated on the corresponding T1 images to compensate for the gap between slices in 
FLAIR (the intra-rater reliability was high [ICC >0.987]) (110). Total intracranial volume 
(TIV) was calculated by adding the GMV, WMV, and cerebrospinal fluid volumes. All 
segmentations were inspected by the SNAC-K neuroimaging expert. All MRI volumetric 
measurements were normalized by TIV and age (111, 112). 
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3.4 COVARIATES 
3.4.1 Sociodemographic factors 
In all datasets, information on age, sex, and education were collected during the baseline 
assessment. Education was categorized as the highest level of formal education attained. 
3.4.2 Vascular risk factors  
VRFs were measured at baseline. Smoking status was classified as never, former, or current. 
Alcohol consumption was categorized into never, occasional, or current ("current" included 
light to heavy drinking) (113). The physical activity variable was based on the intensity and 
frequency of physical exercise and divided into inactive, moderate, or heavy/vigorous (114, 
115). Body weight and height were measured without shoes and without heavy clothes. Body 
mass index (BMI) was calculated as weight in kilograms divided by squared height in meters 
(kg/m2) and categorized as underweight (<20.0), normal weight (20–25), overweight (>25–
30), and obese (≥30). 
3.4.3 Vascular medical conditions and the APOE gene 
Information on medical conditions was available through the Swedish National Patient 
Register, which covers all inpatient care since 1987 and outpatient care since 2001. 
International Classification of Disease-tenth revision (ICD-10) criteria were used to define 
vascular medical conditions. During the physician’s interview in SNAC-K and the nurse’s 
interview in SATSA, arterial blood pressure was measured twice at a 5-min interval on the 
left arm in a sitting position. Diagnoses of vascular conditions were based on the physician’s 
examination, self-report, medication use, or information from the Swedish National Patient 
Register and included hypertension (defined as blood pressure ≥140/90 mmHg), heart 
diseases (atrial fibrillation, bradycardias and conduction diseases, ischemic heart disease, 
cardiac valve disease, and heart failure), or cerebrovascular diseases (stroke or transient 
ischemic attack) (116, 117). The APOE gene was dichotomized into any ε4 allele vs. no-ε4. 
3.4.4 Mortality data 
Participants' vital status was assessed using death certificates from the Swedish Cause of 
Death Registry and medical records at hospital discharge during the study period. 
3.4.5 Lifestyle 
Leisure activities. . At baseline, participants were asked how often in the past 12 months 
they had engaged in activities on a predefined list of 26 mental, social, or physical activities 
(118). Mental activities included those that primarily required mental engagement (i.e., 
reading books, playing chess/cards, playing a musical instrument, listening to music, using 
the Internet or playing computer games, and painting/drawing/working with clay). Level of 
engagement in mental activities was coded as low (≤1 activity), moderate (2-3 activities), or 
high (≥4 activities). Social activities included those that predominantly involved social 
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interactions (i.e., sports events, cinema/theatre/concerts, museums/art exhibitions, 
restaurants/bar/cafés, bingo, dancing, church service, traveling, volunteering, study 
circles/courses, and other social meetings). Level of engagement in social activities was 
coded as low (no activities), moderate (1 activity), or high (≥2 activities). Physical activities 
were those for which the predominant component was light to vigorous physical activity (i.e., 
walking, jogging, bicycle riding, gym/golf/other sports, gardening work, strolling through the 
woods and countryside picking mushrooms/berries, going hunting/fishing, and home repair 
or car/machine/equipment repair). Level of engagement in physical activities was coded as 
low (performed less than once a week), moderate (performed at least once a week), or high 
(performed more than once a week). A leisure activities index was created by summing the 
level of engagement in mental, social, and physical activities (range 0–6), and coded as low 
(score 0–1), moderate (score 2–3), or high (score 4–6) engagement (118, 119). 
Social network. At baseline, social network was assessed with a validated 10-item 
questionnaire that explored two aspects of social network: social connections and social 
support (120, 121). Raw scores on the items on social connections (marital status, 
cohabitation status, parenthood, friendships, and social network size; frequency of direct or 
remote contacts with parents, children, relatives, neighbors, and friends) and from the five 
items on social support (reported satisfaction with aforementioned contacts; perceived 
material and psychological support; sense of affinity with association members, relatives, and 
residence area; and being part of a group of friends) were standardized into z-scores and 
averaged to create an overall social connection index and a social support index. Each index 
was divided into tertiles on the basis of the score distribution: T1 (poor social network [≤-
0.27] or support [≤-0.10]), T2 (moderate social network [-0.26 to 0.39] or support [-0.09 to 
0.33]), and T3 (rich social network [>0.39] or support [>0.33]). Finally, an overall social 
network index was generated by averaging the social connection and social support indices. 
Social network was then divided into tertiles and coded as poor (≤-0.14), moderate (-0.13 to 
0.30), or rich (>0.30), according to the tertile distribution. 
 
3.5 STATISTICAL ANALYSIS 
In all studies, baseline characteristics of participants by diabetes status (diabetes-free 
participants vs. those with prediabetes and diabetes) were compared using chi-square (χ2) 
tests for categorical variables and one-way ANOVAs for continuous variables (tested with 
Bartlett’s test of homogeneity of variance), followed by pairwise means comparisons with 
Bonferroni correction or quantile regression for heteroscedastic continuous variables. In 
studies I and II, cognitive domains were analyzed as separate outcome variables. The study-
specific statistical methods are described below. An overview of the studies and methods 
included in this thesis is provided in Table 2. 
Study I. Linear regressions were used to estimate the cross-sectional mean differences (β-
coefficients and 95% confidence intervals [CIs]) in cognitive performance in diabetes-free 
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participants (reference) and those with prediabetes or diabetes. Interactions between diabetes 
and VRFs, vascular conditions, or APOE ε4 in predicting cognitive performance were tested.  
Study II. Linear mixed-effects models—including unstructured variance-covariance matrix 
and random effects for intercept and slope for time—were used to explore the differences in 
annual rate of change in cognitive performance in diabetes-free participants (reference group) 
vs. those with prediabetes or diabetes, as function of age (time scale). Models included 
diabetes status (diabetes-free, prediabetes, diabetes), linear term for age at time of assessment, 
and their interaction terms (diabetes status × linear age). The random effects (intercept and 
slope) accounted for both 1) the repeated measured for each person, and 2) the presence of 
twin pairs. The cognitive data were censored after dementia diagnosis.  
Study III. Linear regression models were used to assess the cross-sectional associations 
between diabetes status and brain volumes at baseline. The longitudinal associations between 
diabetes status and annual rate of changes in global cognitive function or in the brain MRI 
markers were assessed with multivariable linear mixed-effect models—including 
unstructured variance-covariance matrix and random effects for intercept and slope for 
follow-up time (time scale). Models included diabetes status, linear term for annual follow-up 
time, and their interaction terms (diabetes status × linear time). The relationship between 
hyperglycemia and cognitive decline was also tested with multivariable mixed-effect models.   
Study IV. Incidence rates (IRs) per 1000 person-years of dementia and dementia subtypes 
were calculated as the number of new cases during follow-up divided by the person-years at 
risk. Cox regression models were used to estimate the hazard ratios (HRs) and 95% CIs of the 
association between diabetes status and dementia (all-cause and dementia subtypes). The 
time-scale was follow-up time, which was the time elapsed from baseline to dementia 
diagnoses or to death or the last examination. The proportional hazard assumption was 
verified by regressing Schoenfeld’s residuals against follow-up time. No violation of 
proportionality was detected. The effect of having both diabetes and an active lifestyle (i.e., 
leisure activities or/and social network) on dementia risk was assessed by combining the 
levels of diabetes (yes, no) with the levels of active lifestyle. 
All statistical models in the four studies (linear regressions, mixed-effect models, and Cox 
regressions) were multi-adjusted for baseline age, education, birth cohort, practice effect 
(Study II only), smoking, alcohol consumption, physical activity, BMI, CVDs, and/or APOE 
ɛ4.   
In supplementary analyses, we first modeled diabetes status as a time-varying exposure 
(studies II and III). Second, we addressed potential reverse causality by censoring the 
outcomes at time of dementia diagnosis or excluding incident dementia during the follow-up 
period (studies III and IV). Finally, we performed multiple imputation by chained equation 
for missing values due to dropout (studies I to IV). 
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All tests were two-tailed, and p-values <0.05 were considered statistically significant. 
Statistical analyses for all studies were performed with Stata SE 13.0 or 14.0 (StataCorp LP., 
College Station, Texas, USA).
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Table 2. Overview of the four studies and methods included in this thesis. 
Study  Title  Data sources  
and design 
Prediabetes & diabetes 
assessment 
Outcomes Statistical analysis 
Study I Early cognitive deficits 
in type 2 diabetes 
SNAC-K 
Cross-
sectional 
Diabetes: self-report, 
medication use, medical 
records, or HbA1c ≥6.5% 
Prediabetes: HbA1c 5.7%–
6.4% in diabetes-free 
participants 
Cognitive performance 
at baseline 
Linear regressions 
Study II Cognitive trajectories 
in prediabetes and 
diabetes 
SATSA 
Longitudinal 
Diabetes: self-report, 
medication use, or FBG ≥7.0 
mmol/L (RBG ≥11.0 mmol/L). 
Prediabetes: FBG 5.6–7.0 
mmol/L (or RBG 7.8–11.0 
mmol/L) 
Cognitive decline in 4 
different domains over 
23 years follow-up 
Mixed-effect models 
with random 
intercept and slope, 
using age (years) as 
the time scale 
Study III Prediabetes and 
diabetes accelerate 
cognitive decline and 
predict microvascular 
lesions 
SNAC-K and  
SNAC-K MRI  
Longitudinal 
Diabetes: self-report, 
medication use, medical 
records, or HbA1c ≥6.5% 
Prediabetes: HbA1c 5.7%–
6.4% in diabetes-free 
participants 
MMSE decline and 
brain MRI changes over 
9 years follow-up 
Mixed-effect models 
with random 
intercept and slope, 
using follow-up time 
(years) as the time 
scale 
Study IV An active lifestyle and 
a rich social network 
counteract the risk of 
dementia related to 
diabetes 
SNAC-K  
Longitudinal 
Diabetes: self-report, 
medication use, medical 
records, or HbA1c ≥6.5%. 
Prediabetes: HbA1c 5.7%–
6.4% in diabetes-free 
participants 
Dementia over 10 years 
follow-up 
Cox regression, 
using follow-up time 
(years) as the time 
scale 
Abbreviations: FBG, fasting blood glucose; HbA1c, glycated hemoglobin; MMSE, Mini-Mental State Examination;  MRI, magnetic 
resonance imaging; RBG, random blood glucose; SATSA, the Swedish Adoption/Twin Study of Aging; SNAC-K, Swedish National Study 
Aging and Care-Kungsholmen. 
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3.6 Ethical considerations 
SNAC-K and SATSA received ethical permissions (registration numbers are reported in 
Table 3) from the Ethics Committee at Karolinska Institutet and the Regional Ethical Review 
Board in Stockholm. Informed consent (written or oral) were collected from all participants 
prior to their inclusion in the study, in accordance with the ethical principles for medical 
research involving humans stated in the World Medical Association’s Declaration of 
Helsinki. 
 
Table 3. List of ethical permits for SNAC-K and SATSA at baseline and follow-ups. 
DATASET Registration numbers 
SNAC-K  
Wave I – baseline 01-114 
Wave II – 1st follow-up 78+ 04-929/3 
Wave III – 1st follow-up 60-72, 2nd follow-up 78+ Ö 26-2007 
Wave IV – 2nd follow-up 72, 3rd follow-up 78+ 2010/447-31/2 
SATSA 84:61; 98-319; 2010/657-31/3 
Registries  
SNAC-K permit to use register data 2009/595-32 
Abbreviations: SNAC-K, Swedish National Study on Aging and Care-Kungsholmen; SATSA, the 
Swedish Adoption/Twin Study of Aging 
 
In SNAC-K, participants were informed both by letter and in person. Two weeks before 
assessment, a letter was sent to explain the study’s purpose and duration, interview process, 
and the importance of participation. Participants were informed that participation was 
voluntary and that they could withdraw at any time and without explanation. If a person had 
cognitive impairment, a proxy (i.e., close family member or guardian) was asked for consent. 
Afterward, nurses telephoned only those who agreed to participate and scheduled an 
appointment. The examination process took place in a friendly and comfortable environment. 
During the examination, if the participant expressed anxiousness or discomfort, the interview 
was terminated. As part of the informed consent process, participants were assured that their 
data would remain confidential and anonymous.   
Similarly, in SATSA, all participants received a letter that described the purpose, content, and 
duration of the study and were assured confidentiality and anonymity as part of the informed 
consent process. Participants were informed that their involvement in the study was voluntary 
and that they were free to drop out at any point in time.  
For data collected through the registry system, ethical requirements clearly state that the 
consent must be voluntary. This means that information on the health status of participants 
who dropped out was not available from registries, with the exception of data on vital status 
(if participants was alive or died), which is not covered by privacy law. Risks to privacy have 
been further minimized by assigning one administrator to access the registries and limiting 
the information accessible. In all datasets, researchers obtained anonymized data without any 
reference to a person’s name or personal identification number; data were tagged with only a 
study-specific ID number.
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4 RESULTS 
This section reports the main results of the thesis. For more details on the results of each 
study, please refer to the published papers and the manuscripts included in the thesis. 
 
4.1 DIABETES AND COGNITIVE DOMAIN-SPECIFIC DEFICITS 
In Study I, of the 2305 cognitively intact participants, 571 (24.8%) had prediabetes. One 
hundred ninety-six (8.5%) had diabetes, 144 of whom had uncontrolled diabetes. Participants 
with prediabetes or diabetes were more likely than those without diabetes to be older, male, 
and more physically active; consume less alcohol; and to have fewer years of formal 
education, higher BMI, hypertension, heart disease, and/or lower MMSE scores. Participants 
with prediabetes or diabetes had lower mean performance in all cognitive domains than 
diabetes-free older adults.   
Early deficits in cognitive domains associated with diabetes. Age, sex, and education-
adjusted linear regressions showed that participants with diabetes had lower perceptual speed 
(β -1.98 [95% CI -1.98, -0.23]; p=0.014), category fluency (β -1.27 [95% CI -2.52, -0.03]; 
p=0.045), and digit span forward (β -0.35 [95% CI -0.54, -0.17]; p=0.000) performance than 
those who were diabetes-free (Figure 7). No significant association between prediabetes and 
cognitive performance was detected. After multi-adjustment for VRFs, physical activity, 
CVDs, and depression, only the association between diabetes and poor performance in the 
digit span forward test remained significant (β -0.21 [95% CI -0.39, -0.02]; p=0.027).    
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Figure 7. Association between prediabetes and diabetes and performance across cognitive 
domains. 
Mean differences (β-coefficients) in cognitive performance in participants with prediabetes (striped 
bar) or diabetes (solid purple bar). The reference group consisted of those who were diabetes-free, 
and the results were adjusted for age, sex, and education. 
* p-values for the comparisons between people with prediabetes or diabetes and those who were 
diabetes-free were <0.05. 
 
Factors modulating the link between diabetes and cognitive deficits. We investigated 
whether having diabetes and VRFs, diabetes and CVDs, or diabetes and APOE ɛ4 predicted 
cognitive performance in the different domains. Significant  and marginally significant two-
way interactions (p-values ranging from 0.020 to 0.062) suggested differential cognitive 
performance in people with and people without smoking history, those who were and were 
not overweight/obese, and those who did or did not have CVDs. Diabetes combined with 
current/former smoking, overweight/obesity, or CVDs was associated with poorer cognitive 
perceptual speed (smoking: β -1.59 [95% CI -2.50, -0.35]; overweight/obesity: β -1.63 [95% 
CI -2.58, -0.67]; CVDs: β -2.90 [95% CI -4.01, -1.80]) and category fluency performance 
(smoking: β -1.69 [95% CI -3.21, -0.18]; overweight/obesity: β -1.36 [95% CI -2.75, -0.04]; 
CVDs: β -2.44 [95% CI -4.05, -0.83]), than being diabetes-free and not having the respective 
risk factors (Figure 8, panels A–C). In stratified analyses by APOE ɛ4 allele, people who had 
diabetes and did not carry the ɛ4 allele performed worse in perceptual speed (β -1.11 [95% CI 
-2.15, -0.06]) and digit span forward (β -0.36 [95% CI -0.58, -0.14]) tasks than people who 
were diabetes-free and did not carry the ɛ4 allele (Figure 8, panel D). However, the 
differences in digit span forward performance were not present in people who carried the ɛ4 
allele. 
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Figure 8. Association between combinations of risk factors (diabetes and vascular risk factors, diabetes and cardio- 
and cerebrovascular disorders, and diabetes and the apolipoprotein E gene-ɛ4 allele) and cognitive function. 
The figure shows the multi-adjusted (by age, sex, education, and all remaining covariates) β-
coefficients estimated from four separate linear regression models for the associations between A) 
diabetes and smoking (reference group: people who were diabetes-free and did not smoke), B) 
diabetes and BMI (reference group: people who were diabetes-free and had a normal BMI), C) 
diabetes and CVD (reference group: people who were diabetes-free and did not have CVD), and D) 
diabetes and APOE ɛ4 (reference group: people who were diabetes-free and did not carry the ɛ4 
allele) and cognitive performance in three domains.  
* p-value <0.05; ** p-value<0.01. 
Abbreviations: APOE ɛ4, apolipoprotein E gene-ɛ4 allele; BMI, body mass index; CVDs, cardio- and 
cerebrovascular disorders.  
 
4.2 TRAJECTORIES OF COGNITIVE DECLINE IN PEOPLE WITH 
PREDIABETES OR DIABETES 
In Study II, of the 793 cognitively intact older adults at baseline in SATSA, 68 (8.6%) had 
prediabetes and 45 (5.7%) had diabetes. Participants with prediabetes or diabetes were older 
than those who were diabetes-free. They were also more likely to be overweight or obese, to 
have hypertension, to have a lower MMSE score, and to perform worse in tests of perceptual 
speed and memory. The three groups did not differ significantly with regard to other VRFs, 
CVD, or whether they carried the APOE ɛ4 allele. During follow-up (mean 13.7 ± 6.6 years 
[range=3–23 years]), 361 (45.5%) participants died, 284 (35.8%) participated in all waves, 
120 (15.1%) participated in at least two waves, and 28 (3.5%) only participated in the 
baseline assessment.  
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In Study III, of the 2746 dementia-free older participants at baseline in SNAC-K (947 
[34.5%] had prediabetes and 242 [8.8%] had diabetes), 651 (23.7%) died over a mean follow-
up of 6.4 ± 1.7 years (range=2.1–10.3 years).  
Table 4 shows the differences between SATSA and SNAC-K in baseline characteristics of 
participants and those who died during follow-up. Overall, the differences between 
participants and those who died were similar in the two datasets. Those who died were, on 
average, older than those who participated. They were also more likely to have a low level of 
education, consume less alcohol, and have worse health status than participants.  
 
Table 4. Baseline characteristics of participants and of those who died during follow-up in SATSA 
and SNAC-K.  
 SATSA study SNAC-K study 
Baseline 
characteristics 
Participants* Death 
p 
Participants Death 
p 
n=404 n=361 n=1642 n=651 
Age (years) 58.4 ± 6.7 69.0 ± 7.4 <0.001 68.8 ± 8.4 81.8 ± 8.9 <0.001 
Female sex  250 (61.9) 200 (55.4) 0.07 1023 (62.3) 388 (59.6) 0.231 
Low education † 187 (48.1) 112 (31.9) <0.001 1481 (90.2) 500 (77.0) <0.001 
Currently smokers 181 (46.5) 162 (46.4) 0.976 908 (55.6) 348 (53.6) 0.382 
Alcohol consumption 353 (87.4) 288 (79.8) 0.004 1252 (76.5) 338 (52.4) <0.001 
BMI (kg/m2)        
Underweight (<20) 16 (4.0) 20 (5.5) 
0.487 
46 (2.8) 74 (11.4) 
<0.001 Normal (≥20–25) 184 (45.5) 149 (41.3) 682 (41.5) 306 (47.0) 
Overweight (≥25–30) 152 (37.6) 148 (41.0) 688 (41.9) 211 (32.4) 
Obese (≥30) 52 (37.6) 44 (12.2) 226 (13.8) 60 (9.2) 
Diabetes status        
Diabetes-free 359 (88.9) 299 (82.8) 
<0.001 
1008 (61.4) 306 (47.0) 
<0.001 Prediabetes 37 (9.2) 26 (7.2) 523 (31.9) 254 (39.0) 
Diabetes 8 (2.0) 36 (10.0) 111 (6.8) 91 (14.0) 
Hypertension  168 (41.6) 200 (55.4) <0.001 1116 (68.0) 474 (72.8) 0.023 
Heart diseases 33 (8.4) 62 (17.3) <0.001 230 (14.0) 298 (45.8) <0.001 
Cerebrovascular 
disease 
1 (0.3) 6 (1.7) 0.043 59 (3.6) 73 (11.2) <0.001 
Any APOE ɛ4  103 (27.4) 88 (33.9) 0.094    
MMSE score 28.6 ± 1.3 28.9 ± 1.5 <0.001 29.2 ± 1.0 28.0 ± 1.8 <0.001 
Data are presented as mean ± standard deviations or proportion (%). 
* Participated in at least two or all waves of assessment.   
† A low level of education was defined as <9 years of schooling (SATSA) or an elementary school 
education (SNAC-K). 
Abbreviations: APOE ɛ4, apolipoprotein E gene-ɛ4 allele; BMI, body mass index; MMSE, Mini-Mental 
State Examination; SATSA, The Swedish Adoption/Twin Study of Aging; SNAC-K, Swedish National 
Study on Aging and Care. 
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Cognitive trajectories in people with prediabetes and diabetes. In SATSA, people with 
diabetes had a faster decline in verbal abilities over time (βslope -0.19 [95% CI -0.33, -0.04]; 
p=0.014) and perceptual speed (βslope -0.25 [95% CI -0.44, -0.05]; p=0.012) than those who 
were diabetes-free. Participants with prediabetes had worse memory performance at age 65 
(βintercept -2.19 [95% CI -4.16, -0.10]; p=0.035) than those who were diabetes-free, memory 
function in those with prediabetes declined less steeply over time (βslope 0.15 [95% CI 0.00, -
0.30]; p=0.050) (Figure 9). Results were similar after adjustment for VRFs and CVDs. 
 
 
Figure 9. Trajectories of cognitive decline by diabetes status across domains (Study II). 
The figure shows the trajectories of cognitive decline, as a function of age, in verbal abilities (A), 
spatial/fluid abilities (B), memory (C), and perceptual speed (D) in older adults with prediabetes (grey 
line), with diabetes (purple line), and who were diabetes-free (black line [reference group]). β-
coefficients for intercepts and slopes were estimated with mixed-effects models adjusted for sex, 
education, birth cohort, and practice effects. P-values in purple indicate significance levels of the 
additional decline in people with diabetes, and p-values in grey indicate the significance levels of the 
intercept in people with prediabetes.  
 
We further examined the trajectories of global cognitive decline (MMSE score) over follow-
up in SNAC-K. After adjustment for baseline age, sex, education, VRFs, and CVDs, 
prediabetes (βslope -0.05 [95% CI -0.09, -0.01]; p=0.008) and diabetes (βslope -0.10 [95% CI -
0.17, -0.03]; p=0.005) were independently associated with a faster global decline over the 
follow-up than being diabetes-free. When MMSE data were censored after dementia 
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diagnosis, the association between prediabetes and faster decline remained similar to the 
associations observed in the initial analysis. However, global cognition declined less steeply 
(and statistically non-significantly) in people with diabetes than in those who were diabetes-
free (βslope -0.03 [95% CI -0.08, 0.01]; p=0.144). As HbA1c was dose-dependently associated 
with faster cognitive decline, regardless diabetes status, we further examined the relationship 
between hyperglycemia (higher quintiles of HbA1c) and changes in MMSE score. The results 
showed that the higher quintiles of HbA1c (n=899 [Q4-Q5: HbA1c ≥5.8%]), which 
corresponded to hyperglycemia, were independently associated with faster cognitive decline 
(Table 5). The reference group in the analyses consisted of those with normoglycemia 
(n=686 [Q1: HbA1c 4.3–5.4%]). 
 
Table 5. β-coefficients (95% confidence intervals) of the association between annual changes in 
Mini-Mental State Examination scores and quintiles of glycated hemoglobin in SNAC-K. Quintile 1, 
in which HbA1c levels corresponded to normoglycemia, was the reference group. In quintiles 4 and 
5, HbA1c levels corresponded to hyperglycemia. 
HbA1c (quintiles) × time (years) 
Basic adjusted  
β (95% CI) * 
p 
Multi-adjusted  
β (95% CI) †  
p 
Q1 (HbA1c 4.3–5.4%) × time Reference  Reference  
Q2-Q3 (HbA1c ≥5.4–5.8%) × time -0.03 (-0.06; -0.004) 0.023 -0.03 (-0.06; 0.01) 0.020 
Q4-Q5 (HbA1c ≥5.8%) × time -0.05 (-0.08; -0.02)  0.002 -0.05 (-0.08; -0.02) 0.003 
MMSE data were censored after dementia diagnosis. 
* Adjusted for baseline age, sex, and education. 
† Adjusted for baseline age, sex, education, smoking, alcohol consumption, physical activity, BMI, and 
CVDs.  
Abbreviations: BMI, body mass index; CI, confidence interval; CVD, cardio- and cerebrovascular 
disorders; HbA1c, glycated hemoglobin; MMSE, Mini-Mental State Examination; Q, quintile; SNAC-K, 
Swedish National Study of Aging and Care-Kungsholmen. 
 
4.3 PREDIABETES, DIABETES, AND STRUCTURAL BRAIN MARKERS 
In Study III, in the SNAC-K MRI sample, 455 participants (136 [29.9%] had prediabetes and 
32 [7.0%] had diabetes) were followed for an average of 5.7 ± 0.7 years (range=2.9–7.1 
years). Participants with prediabetes or diabetes were older and more likely to have heart 
disease than those who were diabetes-free. On average, they also had smaller TBTV, GMV, 
and WMV and higher WMHV than those who were diabetes-free. Thirty-nine participants 
(8.6%) died during follow-up. 
Prediabetes, diabetes, and brain MRI changes. In multi-adjusted linear regression models, 
prediabetes was independently associated with smaller TBTV, especially WMV, and diabetes 
was associated with larger WMHV (Table 6). HV was not associated with prediabetes or 
diabetes. The reference group in the models consisted of those who were diabetes-free.  
   
Results 
 31 
Table 6. β-coefficients (95% confidence intervals) of the cross-sectional associations 
between magnetic resonance imaging markers and diabetes status from linear regression 
models 
Brain volumes *  Prediabetes (n=136)  Diabetes (n=32)  
β (95% CI) † p β (95% CI) † p 
Total brain tissue -18.7 (-33.1; -4.3)  0.011 -18.3 (-44.3; 7.7) 0.167 
Grey matter -9.03 (-19.4; 1.28) 0.086 -5.80 (-24.4; 12.8) 0.540 
Hippocampus -0.08 (-0.24; 0.09) 0.354 -0.09 (-0.39; 0.21) 0.566 
White matter -9.67 (-18.7; -0.68)  0.035 -12.5 (-28.7; 3.67) 0.129 
White matter hyperintensities  1.56 (-0.33; 3.46) 0.106 3.49 (0.06; 6.92) 0.046 
* Brain volumes (mL) were adjusted for intracranial volume and age. 
† Adjusted for sex, education, BMI, hypertension, and heart diseases. 
Abbreviations: BMI, body mass index; CI, confidence interval.  
 
During follow-up, multi-adjusted mixed-effect models that compared those with prediabetes 
or diabetes with the reference group of participants who were diabetes-free showed that 
diabetes was independently associated with a faster increase in WMHV (βslope 0.56 [95% CI 
0.07, 1.05]; p=0.026) (Figure 10). This finding suggests that cerebral microvascular lesions 
accumulate faster in people with diabetes than in those who are diabetes-free. 
 
 
 
Figure 10. Trajectories of change in the volume of white matter 
hyperintensities over six years by diabetes status. 
The figure shows white matter hyperintensity trajectories as a function of follow-up 
time in people with prediabetes (grey line), people with diabetes (purple line), and 
those who were diabetes-free (black line [reference group]). Volume of white matter 
hyperintensities (mL) was adjusted for intracranial volume and age. β-coefficients for 
intercepts and slopes were estimated with mixed-effects models adjusted for sex, 
education, BMI, hypertension, and heart disease.  
Abbreviations: BMI, body mass index; WMH, white matter hyperintensity. 
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Multi-adjusted mixed models showed that regardless of a person’s diabetes status, there was a 
dose-dependent association between hyperglycemia (Q4-Q5 [HbA1c ≥5.8%]) and smaller 
TBTV (βintercept -24.2 [95% CI -41.5, -6.87]; p=0.006), particularly WMHV (βintercept -12.6 
[95% CI -23.6, -1.60]; p=0.025), as well as greater WMHV (βintercept 3.32 [95% CI 1.04, 
5.60]; p=0.004) and faster increase in WMHV over follow-up (βslope 0.30 [95% CI -009, 
0.60]; p=0.058). The reference group consisted of participants with normoglycemia. 
 
4.4 PREDIABETES, DIABETES, AND RISK OF DEMENTIA 
In Study IV, the 2696 participants in SNAC-K who were dementia-free at baseline, including 
921 (34.8%) with prediabetes and 243 (9.2%) with diabetes, were followed for 6.4 ± 1.8 
years (range=2.1–10.3 years). During follow-up, 691 (26.1%) died and 229 (8.6%) declined 
to participate in follow-up or had moved. Those who died were older and more likely to have 
a lower level of education, lower BMI, more CVDs, diabetes, and lower MMSE score at 
baseline than the 1729 who were alive and participated in the SNAC-K follow-ups. 
A total of 246 (9.1%) participants were diagnosed with dementia (IR=15.4 [95% CI 13.6–
17.5] per 1000 person-years) over follow-up, including 128 (52.0%) with AD, 25 (10.2%) 
with VaD, and 33 (13.4%) with mixed dementia. At baseline, those with incident dementia 
were older, more likely to be female, and less likely to have a high level of education than 
older adults diagnosed with dementia during follow-up. They were also more likely to have 
lower BMI, heart disease, CVD, diabetes, a lower MMSE score, and at least one APOE ɛ4 
allele. Finally, they were more likely to be less engaged in mental, social, and physical leisure 
activities and to have a poor social network. 
The incidence rates of dementia and its subtypes per 1000 person-years are displayed in 
Table 7. In multi-adjusted Cox regression models, diabetes was associated with an increased 
risk of dementia, in particular vascular dementia and, marginally, mixed dementia.  
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Table 7. Incidence rates of all-cause dementia, Alzheimer’s disease, vascular dementia, and mixed 
dementia (per 1000 person-years) by diabetes status and hazard ratios and 95% confidence intervals 
of the association between dementia, prediabetes, and diabetes.  
Dementia No. events/ Person-year IR (95% CI) 
Cox regression models 
HR (95% CI) * p 
All-cause      
Diabetes-free 121/9368 13.3 (11.2–15.9) Reference  
Prediabetes 88/5517 16.0 (12.9–19.7) 0.97 (0.72–1.30) 0.835 
Diabetes 37/1339 27.6 (20.0–38.1) 2.23 (1.49–3.33) 0.000 
AD      
Diabetes-free 67/9068 7.39 (5.85–9.39) Reference  
Prediabetes 49/5517 8.88 (6.71–11.8) 0.97 (0.66–1.43) 0.894 
Diabetes 12/1339 8.96 (5.09–15.8) 1.34 (0.69–2.59) 0.388 
VaD      
Diabetes-free 10/9068 1.10 (0.59–2.05) Reference  
Prediabetes 7/5517 1.27 (0.60–2.66) 1.20 (0.44–3.33) 0.718 
Diabetes 8/1339 5.97 (2.99–11.9) 7.11 (2.21–22.9) 0.001 
Mixed      
Diabetes-free 12/9068 1.32 (0.75–2.33) Reference  
Prediabetes 15/5517 2.72 (1.64–4.51) 1.39 (0.63–3.05) 0.410 
Diabetes 6/1339 4.48 (2.01–9.97) 2.55 (0.90–7.23) 0.078 
* Adjusted for baseline age, sex, education, smoking, BMI, CVD, and APOE ɛ4. 
Abbreviations: AD, Alzheimer’s disease; APOE ɛ4, apolipoprotein E gene-ɛ4 allele; BMI, 
body mass index; CI, confidence interval; CVD, cardio- and cerebrovascular disorders; HR, 
hazard ratio; IR, incident rate; Mixed, mixed dementia; VaD, vascular dementia. 
 
Figure 11 shows the age-specific incident rate of dementia by diabetes status. As expected, 
the overall incidence of dementia increased with age in people who were diabetes-free, those 
with prediabetes, and those with diabetes 
 
 
Figure 11. Age-specific incidence rates of dementia per 1000 person-years 
by diabetes status. 
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4.5 THE EFFECT OF ACTIVE LIFESTYLE PLUS DIABETES ON DEMENTIA 
Moderate (adjusted HR=0.59, 95% CI 0.42–0.82) or high (adjusted HR=0.44, 95% CI 0.26–
0.74) engagement leisure activities and moderate (adjusted HR=0.73, 95% CI 0.53–1.01) or 
rich (adjusted HR=0.55, 95% CI 0.38–0.81) social network were associated with a decreased 
risk of dementia. We therefore merged them into single categories: “moderate-to-high” for 
leisure activities and “moderate-to-rich” for social network. To assess the potential that an 
active lifestyle would counteract diabetes-related dementia risk, we created an indicator 
variable. The variable combined diabetes status (no vs. yes) with level of leisure activity (low 
vs. moderate-to-high) or social network (low vs. moderate-to-rich). This dummy variable 
divided the participants in four groups: 1) those who were diabetes-free and had a low level 
of leisure activity and a poor social network (“diabetes-free inactive”); 2) those who were 
diabetes-free but at had at least one active leisure activity or a rich social network (“diabetes-
free active”); 3) those with diabetes, a low level of leisure activity, and a poor social network 
(“diabetes inactive”); and 4) those with diabetes, at least one active leisure activity, or a rich 
social network (“diabetes active”).  
Those in the “diabetes inactive” group had a nearly 6-fold higher risk of dementia than those 
in the “diabetes-free active” group. The adjusted HR of dementia for participants with 
diabetes and an active lifestyle was higher than in the “diabetes-free active” group but 
substantially lower than the risk in the “diabetes inactive” group (HR=1.94, 95% CI 1.09–
3.50). Indeed, the “diabetes active” group’s risk was similar to that of diabetes-free older 
adults with an inactive lifestyle (HR=1.66, 95% CI 0.96–2.89; p=0.071).  
 
4.6 SUPPLEMENTARY ANALYSIS 
Time-varying diabetes status. Prediabetes is not a chronic condition; people with 
prediabetes may transition to having diabetes or being diabetes-free. We therefore modeled 
diabetes status as a time-varying exposure in the mixed-effect models, accounting for the 
length of time that each participant was in each stage before the transition to another stage. In 
Study II, no association between time-varying prediabetes and domain-specific cognitive 
decline was observed. In Study III, the association between time-varying prediabetes and 
cognitive decline was statistically significant, but the association between time-varying 
prediabetes and volumetric brain changes was not.   
Possible reverse causation. In all the longitudinal studies (II-IV), we addressed potential 
reverse causality by censoring the outcome(s) at the time of dementia diagnosis, excluding 
incident dementia during the full follow-up period or during the first follow-up, or excluding 
participants with baseline MMSE ≤27. These results were very similar to those of the initial 
analyses. 
Multiple imputation. In all, studies, we addressed potential bias related to missing values 
with multiple imputation. Results were not altered. 
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5 DISCUSSION 
This thesis investigated the impact of prediabetes and diabetes on different stages of cognitive 
function during aging—from the early appearance of cognitive deficits, through cognitive 
decline, to dementia. It also explored the biological mechanisms underlying diabetes-related 
cognitive decline and identified factors that might protect people with diabetes from 
dementia. 
 
5.1 INTERPRETATION OF THE MAIN FINDINGS 
5.1.1 Diabetes and cognitive aging: from cognitive deficits to dementia 
The findings of this thesis support the notion that diabetes affects the whole process of 
cognitive aging, from being cognitively intact to dementia. The results of studies I and II 
showed that some cognitive domains appear to be more sensitive than others to the impact of 
diabetes. Indeed, diabetes was related to poor performance in perceptual speed, category 
fluency, and attention/primary memory in cognitively intact older people (122). Diabetes was 
also associated with fast decline in perceptual speed and verbal abilities in relatively 
cognitively intact older adults (117). However, the association between diabetes and episodic 
memory was not evident in either cross-sectional or longitudinal analyses (117, 122). These 
findings suggest that diabetes is associated with early deficits in the cognitive domains of 
processing speed, executive function, and attention/primary memory, and furthermore that 
these domains decline faster than others over time. Finally, our results showed that diabetes 
was associated with double the risk of dementia (especially of vascular origin), but that this 
risk could be counteracted, at least in part, by an active lifestyle and a rich social network. 
This suggests the presence of mechanisms that can compensate for and might protect against 
dementia in people with diabetes. 
Although studies consistently observe an association between diabetes and cognitive deficits, 
the domains that are impaired by diabetes early in cognitive deterioration have remained 
unclear. The results of previous research on the associations between diabetes and cognitive 
function in the different subdomains of memory (episodic, semantic, and working) and 
between diabetes and processing speed, attention and executive function, visuospatial 
abilities, and verbal abilities have been highly heterogeneous (see Appendices 1 and 2) (123). 
This heterogeneity is linked to methodological limitations. This doctoral project was able to 
address some of these methodological concerns by using composite domain measures 
extracted by structural equation modeling or principal-component analysis and diagnostic 
tests for prediabetes and diabetes (i.e., HbA1c or blood glucose). Additionally, a major 
limitation of previous studies has been the inclusion of participants with cognitive 
impairment or preclinical dementia in the study populations. AD-related brain and cognitive 
changes are thought to begin about a decade before dementia is clinically diagnosed (124). It 
is extremely important to take this into account when investigating which cognitive domains 
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are impaired early in older adults with diabetes and how this impairment progresses over 
time. If people with cognitive impairment or preclinical dementia are included in such 
studies, the observed diabetes-related cognitive deficits or decline may reflect cognitive 
changes due to causes other than diabetes, such as underlying AD-related degenerative 
processes. In our studies (I and II), we carefully excluded participants with CIND or incident 
dementia, and our results showed that cognitive deterioration in people with diabetes may 
start by affecting fluid abilities (perceptual speed, attention, and executive function), which 
are also those that decline more rapidly over time. This pattern differs from the typical 
cognitive progression observed in AD, which is mostly characterized by disturbances of 
crystallized abilities, particularly of episodic memory (2, 70).  
Overall, our results seem to point toward the existence of vascular-related processes in the 
brain that underlie the early stages of cognitive deterioration in people with diabetes. These 
results are clinically relevant, as they provide practical guidance about cognitive assessment, 
especially the tests to be used to detect diabetes-related cognitive deficits early and to monitor 
their progression. Screening or specific cognitive tests that target fluid abilities—particularly 
psychomotor speed, attention, and executive function—should be preferred to tests that 
predominantly assess crystallized abilities (i.e., the MMSE).   
The role of VRFs, CVDs, and APOE ɛ4. CVD and diabetes are often comorbid (125), and 
VRFs, CVDs, and APOE ɛ4 are also risk factors for dementia and for diabetes (3, 126). Thus, 
it is plausible to believe that these factors might play a role in cognitive dysfunction or 
decline related to diabetes. As expected, in Study I, smoking, overweight/obesity, and CVDs 
contributed to the association between diabetes and cognitive deficits (122). Indeed, the 
negative impact of diabetes on cognitive performance was present in people with diabetes 
and with VRFs or CVDs. However, these factors did not alter the independent association 
between diabetes and accelerated cognitive decline observed in Study II. This suggests that 
VRFs or CVDs can modulate the effect of diabetes on cognitive performance in the initial 
stages of overt cognitive impairment; however, their role in the cognitive progression linked 
to diabetes warrants further investigation. Furthermore, our results also showed that the 
negative impact of diabetes on cognitive performance was present among older adults with 
diabetes but APOE ɛ4 non-carriers; similar results have been described previously (60, 127). 
A possible interpretation is that APOE ɛ4 carriers have already accumulated sufficient AD-
related cerebral biochemical and structural pathology to manifest clinically relevant cognitive 
impairment earlier than non-carriers (124, 127). On the other hand, ɛ4 non-carriers might 
require additional physiological insults, such as diabetes, to reach the threshold for expressing 
clinically relevant cognitive impairment (122, 127).  
 
5.1.2 Prediabetes and cognitive aging 
The associations between prediabetes and cognitive deficits and between prediabetes and 
cognitive decline have been examined in a few previous cross-sectional and longitudinal 
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studies (17, 27, 31, 36, 39, 41, 48, 49); no associations were observed. Partially in line with 
these previous findings, in Study I we found no association between prediabetes and 
cognitive deficits in specific domains among cognitively intact participants. Conversely, we 
found an association between prediabetes and baseline poor memory performance in Study II 
(117). As prediabetes is not a chronic condition, but transitions to normoglycemia or diabetes 
may occur, we also tested prediabetes as a time-varying exposure and found that its negative 
association with memory performance was no longer significant. On the other hand, in Study 
III, prevalent and time-varying prediabetes were associated with faster MMSE decline over 
nine years than was being diabetes-free. Finally, in Study IV, we found no association 
between prediabetes and risk of dementia, which is in disagreement with previous findings 
from the Kungsholmen project (60).  
The Kungsholmen project was the forerunner of SNAC-K; it was conducted between 1987 
and 2000 and included people ≥75 years who lived in Kungsholmen. Prediabetes was 
identified in different ways in the two population-based studies: the Kungsholmen project 
used RBG, and SNAC-K used HbA1c (60, 122). These methods measure different aspects of 
prediabetes. Specifically, HbA1c measures the average proportion of hemoglobin proteins 
bound by glucose over the past three months (128) and as such captures only chronic 
hyperglycemia, not acute hyperglycemia or fluctuation in glycemic levels. The RBG test 
measures the concentration of blood glucose at the moment the blood sample is taken. It is 
therefore likely that observed discrepancies in the findings in the literature and in this thesis 
reflect methodological differences in the ways prediabetes was assessed. The findings of 
Rönnemaa et al. (129) are consistent with this hypothesis. They assessed the relationship 
between different markers of prediabetes and risk of dementia and found that associations 
differed by type of marker.  
Our findings of a possible link between prediabetes and cognitive aging must thus be 
interpreted with caution. Indeed, future studies are needed to investigate whether and to what 
extent different aspects of glucose metabolism (hyperglycemia itself or hyperglycemia 
secondary to insulin-resistance) in the prediabetic stage are linked to the different cognitive 
outcomes. 
 
5.1.3 The role of an active lifestyle and rich social network in diabetes-
related dementia 
The results of Study IV showed that active engagement in leisure activities and a rich social 
network significantly diminished the risk of dementia that was related to diabetes. These 
results suggest that an active and socially integrated lifestyle might counteract the risk effect 
of diabetes on dementia.  
Leisure activities and social network are among the major components of healthy lifestyle 
behaviors in older adults. With advancing age, people may tend to engage less in socially, 
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mentally, and physically challenging activities. However, an active lifestyle and staying 
socially integrated is particularly important in old age. 
Leisure activities are activities that people engage in for enjoyment or well-being during their 
free time. In other words, they are activities independent of work or outside people’s daily 
routines (130). Numerous previous population-based studies have reported that older people 
who are highly engaged in physical, mental, or social leisure activities have a decreased risk 
of cognitive impairment (130) and dementia (3, 118, 131-134). Similarly, intervention studies 
have shown that enhancing leisure-time physical activity substantially reduces the risk of 
diabetes in at-risk adults (135-137). However, those studies focused mostly on the physical 
component of leisure activities, neglecting the mental and social components.  
Social network has been defined as the network of social relationships surrounding a person. 
It therefore includes the person’s social connections, activities, and social support (138). 
Previous studies have found that different aspects of social networks (e.g. network size, 
satisfaction, support) reduce the rate of cognitive decline (139, 140) or risk of dementia (141-
145), although other studies have not found such links (146, 147). Furthermore, a rich social 
network has been associated with a decreased risk of developing diabetes, better glycemic 
control, and better diabetes self-management (148, 149).  
Previous studies have addressed the relationship between lifestyle behaviors and risk of 
dementia or lifestyle behaviors and risk of diabetes. However, no previous epidemiological 
study seems to have investigated the combined counteracting effect of an active lifestyle and 
rich social network on the risk of diabetes-related dementia. Currently there is no 
pharmacological treatment for dementia. Thus, a lot of effort is devoted to identifying 
strategies that may help prevent dementia. In this context, our results are of particular 
importance because they suggest that a sizeable proportion of diabetes-related dementia could 
be delayed by engaging in an active lifestyle; that is, by being highly engaged in leisure 
activities and having a rich social network. Future behavioral interventions should aim to 
understand the extent to which an active lifestyle counteracts the risk of dementia in older 
adults with diabetes.     
 
5.1.4 Biological mechanisms 
Cerebral vascular mechanisms. In Study III, diabetes was associated with larger WMHV at 
baseline and a faster increase in WMHV during follow-up. Prediabetes was also related to 
smaller global brain volume, a finding that mostly reflected smaller white matter volume. No 
association was observed between prediabetes or diabetes and hippocampal volume, an AD-
related degenerative marker. Together, these findings suggest that diabetes may affect the 
brain primarily through vascular pathway linked to the accumulation of cerebral 
microvascular lesions. Also, these vascular brain alterations may already exist in the 
prediabetic stage. 
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WMHs, a sign of SVD, are probably due to progressive demyelination and axonal loss that 
leads to substantial white matter loss and brain atrophy over time, thus contributing to the 
accumulation of brain damage (87). WMH can also contribute to cognitive decline and 
dementia in old age (86, 150, 151). As summarized in the introduction of this thesis, the link 
between diabetes and the progression of WMH has been addressed in four previous 
prospective studies, which reported no differences in the rate of WMH changes in people 
with diabetes vs. people who were diabetes-free (81-84). Differences in study design 
(population-based vs. clinic-based), characteristics of the study sample (demographics, 
methods used to identify prediabetes, sample size), or longer follow-up might explain the 
discrepancies between our and previous findings.  
Diabetes and prediabetes can affect the brain through the oxidative stress-related or 
inflammatory pathways that stem from chronic hyperglycemia (152). Hyperglycemia may 
trigger or exacerbate age-related oxidative stress and inflammatory processes (153). These, in 
turn, lead to dysfunction or disruption of the blood-brain barrier (BBB), damaging the 
microvasculature of the brain over time (154). Compromised BBB integrity is a key 
component in SVD-related changes in white matter (88). Neuroimaging and postmortem 
studies have reported changes in BBB permeability in patients with SVD and found BBB 
leakage in areas of white matter lesions (88). Furthermore, a recent animal study found a 
breakdown in the BBB of diabetic mice (154). In particular, the authors observed changes in 
pericytes and astrocytes, cells responsible for maintaining BBB integrity and that are part of 
the neurovascular unit (155). 
Our results do not rule out the possibility that in people with diabetes, cerebrovascular-related 
degeneration may overlap with AD-related degeneration in the more advanced stages of 
cognitive decline. Indeed, the participants in the MRI sample were relatively healthy and had 
a high cognition function at baseline (their mean MMSE score was 29). If these people were 
in cognitive decline, they were likely in its initial stages, as further supported by the minimal 
but statistically non-significant differences in the rate of cognitive decline over follow-up in 
the participants with diabetes and those without (see manuscript III). Additionally, previous 
studies have reported that diabetes is related to an increased risk of AD (59, 156, 157), and 
the majority of dementia cases have mixed vascular and AD-related neuropathology (65, 
158). Unexpectedly, in our SNAC-K sample, we found no association between diabetes and 
AD. Future studies could focus on the question of whether cognitive decline in people with 
diabetes initially occurs through the vascular pathway and later overlaps or interacts with 
separate neuropathology related to AD. If such overlap or interaction is observed, the studies 
could seek to identify the stage of cognitive aging at which the overlap or interaction begins.   
Cognitive reserve. The theory of cognitive reserve stems from the numerous epidemiological 
studies showing that dementia risk is reduced in older people who were exposed to certain 
factors over the course of their lives, such as a high level of education, complex 
occupation(s), or an active lifestyle (159, 160). The theory attempts to explain the 
discrepancies between the person’s relatively preserved cognitive performance and brain 
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pathology levels typically associated with the impaired cognitive performance (159). 
According to the cognitive reserve theory, the experiences accumulated during the lifespan 
help shape the person’s neuronal activity and networks, improving the person’s cognitive 
efficiency, capacity, and flexibility or providing new compensatory cognitive networks that 
can be used during brain changes (159). It follows that older people with high cognitive 
reserve will cope better with brain pathology by using preexisting neuronal reserve or 
activating compensatory networks to maintain their cognitive performance (159, 161). Our 
finding that an overall active lifestyle and rich social network may substantially reduce the 
risk of diabetes-related dementia can be explained in terms of cognitive reserve. Social 
networks prompt people to interact by engaging in verbal and nonverbal communication, thus 
helping to maintain cognitive abilities in old age. Similarly, leisure activities challenge people 
mentally, physically, and socially. An active and socially integrated lifestyle may therefore 
help older adults with diabetes to keep their cardiovascular and brain health, preserving their 
brain chemistry, structure, and function. This would help people with diabetes to maintain 
their brain capacity by resisting ongoing vascular-related brain changes (162) or activating 
compensatory networks to cope with the underlying neurovascular pathology and maintain 
their cognitive performance level (161). 
 
5.2 METHODOLOGICAL CONSIDERATIONS  
5.2.1 Study design 
All studies in this thesis were longitudinal, population-based, observational studies, except 
Study I, which was cross-sectional. In cross-sectional studies, exposures (diabetes) and 
outcomes (cognitive performance) are observed simultaneously at a specific point in time 
(baseline assessment), preventing the establishment of a temporal relationship between the 
two. Additionally, cross-sectional studies assess differences in the outcome between two or 
more groups of individuals (interindividual variability), which makes it difficult to rule out 
possible intraindividual effects, such as those related to cohort differences in people of 
different ages (163).  
With regard to the sources of the study populations, both SNAC-K and SATSA had few 
exclusion criteria (e.g., age <60 or <50; inability to speak Swedish). Furthermore, as 
consequence of the recruitment strategies (random sampling of 11 age-cohorts in SNAC-K 
and from the Swedish Twin Registry in SATSA), the study samples can be considered 
representative of the population living in Kungsholmen (SNAC-K) or in Sweden (SATSA).     
 
5.2.2 Sources of errors 
One of the aims of epidemiological studies is to obtain valid and precise estimates (estimates 
with little error) of the effect of an exposure on an outcome. There are two main types of 
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error in observational studies: 1) systematic error, or bias, related to the way the study was 
conducted (selection of the study population, measurement of variables, control for potential 
confounders) and 2) random error, the random variability that is left after the systematic error 
has been addressed and that is thus difficult to predict (164).   
Systematic error (lack of internal validity). Systematic errors or bias can be classified in 
three broad categories: selection bias, which includes attrition; information bias; and 
confounding. 
1) Selection bias. Selection bias is a distortion in the association between the exposure and 
outcome that is linked to the procedure used to select the study sample. Selection biases 
can arise when only certain people in an initially randomly selected group choose to 
participate in a study, and those people share specific characteristics. For instance, the 
people who chose to participate in SNAC-K or SATSA might have been generally 
healthier (cognitively and physically) than those who declined to participate; this 
pheomenon is called the healthy respondent effect. In SNAC-K, the 1227 people who 
declined to participate in the baseline survey were more likely to die shortly after the 
beginning of the study than those who chose to participate (165), which supports the 
hypothesis that participants were potentially healthier than those who declined to 
participate. Similarly, we compared the baseline characteristics of participants and non-
participants in the SNAC-K MRI sample. Overall, participants in the MRI sample were 
younger, relatively healthier, and had better cognitive function than those who were not 
scanned. The use of self-selected healthier participants therefore might have lead to an 
underestimation of the effect of the exposure on the outcomes. Unfortunately, in SATSA 
was not possible to quantify the healthy-respondent effect because health-related data were 
only available for people who agreed to participate.  
 
Additional selection bias may have come from values missing because of non-response 
(dropouts) and attrition (death). In studies II through IV, we used multiple imputation to 
understand how data missing because of drop-out would have affected the observed 
associations. The results of these secondary analyses showed associations similar to those 
found in the initial analyses. We also investigated the potential impact of attrition on our 
results. The attrition rates in SNAC-K varied between nearly 24% (over six years) and 
26% (over 10 years), which is quite low; in SATSA, the attrition rate was about 45% over 
23 years. To understand how the attrition affected our results, in studies II to IV, we 
compared the baseline characteristics of those who participated and those who died. Those 
who died were less healthy overall (they had worse cognitive and physical function) than 
participants. The differences in baseline characteristics between participants and those 
who died in SNAC-K were similar to those observed in SATSA. Therefore, in this 
scenario, sample selection probably led to a more advantaged study population and thus an 
underestimation of the negative effect of prediabetes and of diabetes on cognitive 
outcomes. 
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2) Information bias. Information biases can arise from the measurements used to collect 
information about or from people (166). For categorical variables, measurement error can 
lead to assign the person to an incorrect category, therfore the person is misclassified. 
Exposures, outcomes, and other variables can be misclassified in two ways: 
 
• “Non-differential” misclassification results from the degree of inaccuracy in the 
methods used to collect the data (random error). It occurs when different groups (e.g., 
exposed and unexposed) have the same probability of being misclassified, 
independently of other variables. Non-differential misclassification is of interest in 
both the exposure and the outcome; therefore, in this thesis, this type of 
misclassification would have arisen from the assessment of diabetes, prediabetes, 
cognitive outcomes, or dementia. 
• “Differential” misclassification is related to systematic error. It occurs when different 
groups (e.g., exposed and unexposed) have different probability of being 
(mis)classified depending on the person’s disease/status. For example, differential 
misclassification would occur if the exposure were more likely to be misclassified for 
people with than those without the outcome.  
 
Ascertainment of exposure. Non-differential misclassification of the exposures (i.e., 
prediabetes and diabetes) is a potential source of information bias. The recommended 
standard diagnostic tests for detecting diabetes and prediabetes are based on HbA1c or 
blood glucose levels—either FBG or an oral glucose tolerance test (measuring blood 
glucose 2 hours after drinking 75 g of glucose)  (98). SNAC-K used the HbA1c test to 
identify diabetes (including undiagnosed diabetes) and prediabetes, and SATSA used the 
FBG or RBG test. The concordance between these tests is imperfect, partly because of the 
intrinsic limitations of the tests and partly because they measure different markers of 
hyperglycemia. Indeed, HbA1c measures the average proportion of hemoglobin proteins 
bound by glucose over three months prior to the blood test (128). As such, it is likely to 
capture the chronic hyperglycemia but not acute hyperglycemia or fluctuations in 
glycemic level. The HbA1c test has several advantages: unlike the tests that measure 
blood glucose levels (i.e., FBG, RBG, and oral glucose tolerance), fasting is not needed, 
and the HbA1c test is less vulnerable than the others to day-to-day variability due to stress 
or illness (98). Some studies show that HbA1c is less sensitive than FBG and oral glucose 
tolerance in detecting people with diabetes or impaired glucose tolerance (137, 167, 168), 
but one other study did not find such a difference in sensitivity (169). It follows that in our 
samples, some prediabetes or diabetes cases might have been misclassified, leading to a 
dilution of the observed associations. Therefore, even if there is an association between 
prediabetes or diabetes and cognitive outcomes, we might not have detected it or we might 
have underestimated its magnitude. 
Ascertainment of outcomes. Non-differential misclassification of the outcomes is another 
potential source of information bias. In studies I and II, cognitive function was measured 
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with composite scores from neuropsychological tests. These scores have the advantage of 
increasing reliability and reducing measurement error (i.e., ceiling/floor effects) (117, 
122). However, in Study III, prediabetes- and diabetes-related cognitive decline was 
assessed with the MMSE. Although the MMSE has numerous advantages, this cognitive 
screening test also has several limitations. First, the MMSE has both ceiling and floor 
effects: the higher scores do not necessarily reflect complete absence of cognitive 
impairment, and the lower scores do not necessarily reflect the absolute presence of severe 
impairment (170). Second, the MMSE lacks items that assess processing speed and 
attention/executive function that seems to be affected early by diabetes. As consequence, 
the MMSE may not be sensitive enough to detect subtle cognitive changes in the early 
phase of cognitive impairment, particularly among well-educated adults such as the 
SNAC-K participants. These intrinsic limitations of the MMSE could have led to 
underestimating or not detecting the effect of prediabetes or diabetes on cognitive decline. 
However, MMSE scores correlate well with several global brain measurements (171), 
which were the main focus of study III.   
Differential classification can also occur when only self-reported information is used to 
assess a variable. For example, the probability of recalling relevant information may be 
different in people who develop dementia and those who do not. In Study IV, participants 
without incident dementia might have reported more accurate information on leisure 
activities and social network because their memory functioned well, whereas participants 
with incident dementia might forget them and report less accurate information. In this 
case, the observed effects of active lifestyle on dementia risk might have been 
underestimated or overestimated. After excluding participants who developed incident 
dementia between baseline and the first follow-up and/or who had an MMSE score ≤27, 
the associations were unchanged. Finally, differential misclassification might have arisen 
from using other self-reported information to identify, for example, medical conditions. To 
avoid differential misclassification of medical conditions, self-reported information was 
not the only kind used; we also obtained information on medical conditions from other 
sources, including registries, physician examination, and participants’ proxies. 
Additionally, in all studies, we either excluded participants with dementia in the main 
analysis or in secondary analysis. The results of such secondary analyses were similar to 
those of the initial analyses.   
3) Confounding. A confounder is a known risk factor for the outcome that is associated with 
but not caused by the exposure (if it were caused by the exposure, it would be a mediator) 
(172). When the effect of the exposure on the outcome is mixed with the effect of other 
variables on the outcome, the final effect of the exposure will either be overestimated or 
underestimated. We considered the major known confounders in all our analyses by 
adjusting the statistical models for these factors (e.g., demographics, VRFs, CVDs, APOE 
ɛ4). Additionally, for confounding to occurr, the distribution of the third variable in the 
strata of the exposure should differ. Therefore, in each study, we tested for possible 
interactions (additive and multiplicative) between the exposure and possible confounders 
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in predicting the outcomes and performed stratified analyses. However, although various 
exposure and potential confounders were considered in this thesis, as in all 
epidemiological studies, unmeasured confounding due to unknown factors could still have 
ocurred.  
 
Possible reverse causality and critical periods. Two main challenges in research on the 
determinants of cognitive aging and dementia are: 1) the possibility of reverse causation and 
2) the critical periods or time windows in which the exposure exerts a risk effect on the 
outcome. Reverse causality occurs when the outcome causes the risk factor rather than vice 
versa. Therefore, it is important to consider whether the exposure really came before the 
outcome or the outcome (e.g., dementia) may have started to develop before the exposure 
(173). Specifically, in this thesis, given that the preclinical phase of dementia can begin about 
20 years before clinical diagnosis (5), the observed associations between diabetes and 
cognitive outcomes (cognitive deficits, decline, brain changes, and dementia) might be 
attributable to preclinical dementia rather than to diabetes itself. We attempted to control for 
potential reverse causality by excluding people with CIND at baseline, who developed 
dementia over follow-up, and/or including only participants with MMSE score ≥28 (in the 
main or supplementary analyses). Another important issue to consider in research on diabetes 
and cognitive aging research is the critical time windows when prediabetes and/or diabetes 
occur (midlife, late-life, or changes over time) and their impact on cognitive decline. In 
SATSA and SNAC-K, repeated measures of diabetes (at different ages) were available, 
which provided the opportunity to test whether time-invariant and time-varying prediabetes 
or diabetes affected cognitive decline differently.        
Random error. Major sources of random error are related to population sampling and to 
measurement (164). The ideal way to investigate a phenomenon (such as the relationship 
between diabetes and cognitive aging), would be to investigate it in the whole population. 
However, in the real world, this is not possible. Instead, during the sampling process, we 
select a random sample that is representative of the population of interest and calculate 
sample statistics and estimates (e.g., mean, SD, median, β-coefficients, HR). The random 
error due to the sampling procedure can be reduced by increasing the sample size. Random 
errors can also occur because of the limited precision of devices, tools, and/or methods used 
to measure the exposure (e.g., laboratory techniques used to measure HbA1c), the outcome 
(e.g., cognitive tests), or other variables. Random error due to measurement errors can be 
minimized by collecting and averaging several measurements of the same variable. 
 
5.2.3 Generalizability or external validity 
Epidemiological studies attempt to use randomly selected samples from a broader target 
population. The random sample should be representative of the study sample. That is, it 
should share the same characteristics as the target population. This is because the ultimate 
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goal of observational studies is to generalize what is observed in the random sample to the 
larger targeted population. Nevertheless, systematic errors (e.g., selection and information 
bias, confounding) may lead to incorrect estimates of the association between exposure and 
outcome, compromising the generalizability of the findings. When we draw conclusions from 
any epidemiological study, we must keep in mind that no study population can be fully 
representative of all other populations because every study population has unique 
characteristics.  
SNAC-K. Participants in SNAC-K live in Kungsholmen, a neighborhood in central 
Stockholm. SNAC-K participants have high levels of education and are relatively healthy and 
wealthy (174, 175). This possible selection bias might have led to an underestimation of the 
observed associations. Consequently, the effect of diabetes on different stages of cognitive 
aging found in this doctoral project can be generalized to the entire population of older adults, 
independent of their unique characteristics. However, the magnitude of the observed effects 
would vary according to the unique characteristics of the populations. Thus, the magnitude of 
the observed effects can be generalized only to populations with characteristics similar to 
those of the SNAC-K population.  
SATSA. SATSA included twins living all over Sweden who were reared apart from each 
other and a matched sample of twins brought up together. A common criticism of twin 
studies is that results from twins might not be applicable to non-twins, which would mean 
that the results of twin studies were not generalizable to the wider general population. 
However, previous studies have shown that the twins in the Swedish Twin Registry are much 
like the people in the general Swedish population (176). Additionally, in our SATSA-based 
study, we controlled the analyses for the fact that twins are individuals who are genetically 
related. We did this by adding two random effects, each of which included a random intercept 
and a random slope for age: one for the person-specific identifier and one for the twin-pair 
identifier. We are thus confident that the results of Study II can be generalized to the general 
population of non-twins.   
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6 CONCLUSIONS 
 
I. In cognitively intact older adults, diabetes was cross-sectionally associated with 
poorer performance in fluid abilities, in particular in perceptual speed, category 
fluency, and attention/primary memory tasks. These associations were present in 
older adults with diabetes and VRFs (smoking or overweight/obesity) or CVDs and 
in APOE ɛ4 non-carriers. In sum, the results suggest that fluid abilities can be 
affected by diabetes early in the process of cognitive deterioration. Moreover, 
diabetes may not be the sole factor contributing to the observed cognitive deficits. 
 
II. Longitudinally, diabetes accellerated cognitive decline in perceptual speed and 
verbal abilities, independently of VRFs, CVDs, and the APOE ɛ4 allele. Although 
people with prediabetes had poorer baseline memory performance than those who 
were diabetes-free, memory function in those with prediabetes declined less steeply 
over time. 
 
III. Prediabetes and diabetes were associated with accellerated global cognitive decline. 
At the structural brain level, prediabetes was associated with smaller total brain 
volume, particularly white matter volume, but only at baseline. WMH accumulated 
faster over time in those with diabetes than those who were diabetes-free. The 
results suggest that microvascular processes may play a fundamental role in 
prediabetes- and diabetes-related cognitive decline.  
 
IV. Diabetes was associated with an increased risk of dementia, particularly of vascular 
origin, whereas the association between prediabetes and dementia was not evident. 
However, higher engagment in mental, physical, and social leisure activities and/or 
having a rich social network could significantly counteract the detrimental effect of 
diabetes on dementia. 
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7 RELEVANCE AND IMPLICATIONS  
Today’s epidemic of diabetes and dementia is without precedent, and the number of people 
with each of these two diseases is expected to double, even triple, in the next three decade as 
the older population continues to grow (4, 11). Consequently, both diseases will pose critical 
challenges to health care systems around the world, becoming two of the largest public health 
emergencies of the twenty-first century. 
The onset of dementia occurs nearly two decades before clinical diagnosis, and several 
cardiometabolic risk factors contribute substantially to its onset in late life (5, 7). Indeed, 
diabetes is one of the seven main causes of dementia (7). Currently, there is no cure for 
dementia, but preventing it by postponing the symptoms seems achievable (3, 177). 
Promising findings from epidemiological studies suggest that an active lifestyle might 
provide sufficient cognitive reserve to enable people to cope with accumulating lesions in the 
aging brain, including AD-related pathology. In this scenario, the most effective strategy for 
preventing dementia (i.e., reducing or delaying symptoms) in people with diabetes could be 
preventing cardiometabolic diseases through combined pharmacological and multidomain 
lifestyle/behavioral interventions. 
The findings of this thesis have relevant clinical implications. First, understanding cognitive 
trajectories and the different combinations of modifiable risk factors may help with the early 
identification of people with diabetes who are at risk of dementia. This, in turn, will allow for 
timely initiation of preventative strategies (such as individually tailored interventions), thus 
delaying progression to dementia. Second, although our understanding of the 
pathophysiology of AD has advanced considerably in the last twenty years, thus far, clinical 
trials of new disease-modifying drugs have failed to produce meaningful and long-lasting 
cognitive improvements (178). A reason the traditional treatment options for AD might be 
inadequate—and one that might partly explain the failure of clinical trials—could be that the 
trials targeted the wrong people (e.g., those with mixed dementia rather than pure AD) and 
perhaps provided the intervention at the wrong time (e.g., too late). Indeed, dementia is a 
multifactorial disease, and AD is only one of the causes. Mixed pathologies (vascular and 
AD-neurodegenerative) lie behind most cases (158). Future clinical trials therefore need to 
include the right participants (e.g., pure AD) and take into account the potential overlapping 
etiology of most dementia cases. With this in mind, it is possible that interventions based on 
the combination of different therapeutic approaches (drugs and lifestyle change) that address 
multiple targets (e.g., cardiometabolic health and AD-related pathology) could be effective 
future strategies for preventing dementia in people with diabetes. 
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8 FUTURE DIRECTIONS 
This doctoral thesis built on and extends the existing literature on diabetes and cognition.  
The results add another piece to the puzzle about how prediabetes and diabetes impact 
different degrees of cognitive function during cognitive aging. However, to complete the 
puzzle, we need more long-term longitudinal studies that integrate data from comprehensive 
neuropsychological batteries with data on AD-related and vascular biomarkers—for example, 
from neuroimaging, cerebrospinal fluid, or blood (e.g., Aβ-plaque, tau, inflammatory 
cytokines, or oxidative stress markers).   
To improve the process of predicting and diagnosing dementia as well as the outcomes of 
clinical trials, further steps are needed. First, we should map the cognitive profiles of the 
different brain pathologies (pure AD, vascular dementia, and mixed dementia) in people with 
diabetes. In particular, we need to understand whether and to what extent the cognitive 
characteristics of older adults with pure AD, vascular dementia, or mixed pathologies differ 
in the different stages of cognitive aging (from intact cognition, through cognitive decline, to 
cognitive impairment and dementia). Second and equally, we need to understand the 
trajectories of systemic, biochemical, cerebral, and cognitive markers in the cognitive profiles 
that characterize the different brain pathologies. Third, given the symbiotic relationship 
between the brain and the heart and the clustering of diabetes with other cardiometabolic 
conditions (hypertension, overweight/obesity, and heart disease), we also need to address the 
combined contributions of these cardiometabolic conditions to cognitive and brain 
deterioration. Fourth, considering the discrepancies in the findings on this topic, future 
studies on the link between prediabetes and cognitive aging need methodological 
improvements, particularly in the markers they use to assess prediabetes. Fifth, further 
investigation is warranted into the details of the possible neuroprotective role of cognitive 
reserve (and other related concepts such as brain maintenance) over the entire life course. It is 
possible that different factors (e.g., education, occupational complexity) related to cognitive 
reserve may interact in complex ways over time to build up this reserve and thus protect 
people with prediabetes or diabetes from developing dementia.. Finally, the findings of this 
thesis can be useful in designing multidomain intervention that explore whether and to what 
extent the combination of hypoglycemic drugs and lifestyle modification can delay the 
progression to dementia in people with diabetes.   
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11 APPENDICES  
11.1 SUMMARY OF THE CROSS-SECTIONAL AND CASE-CONTROL STUDIES ON THE RELATIONSHIP BETWEEN PRE/DIABETES 
AND COGNITIVE DEFICITS 
Reference Study population Prediabetes Diabetes Cognitive domains Results Covariates 
Geijselaers et al. 
2017 (17) 
Netherlands 
Population-based 
n=2531 
Mean age 60 yrs. 
OGTT 7.8-
11.0 mmol/L 
Medication use 
OGTT ≥11.1 
mmol/L 
 
Composite from z-scores: 
Memory 
Processing speed 
Attention/executive  
Diabetes had poor 
performance in all 
domains. 
 
No association for 
prediabetes 
Age, sex, education 
Fink et al. 
2017 (179) 
Germany 
Population-based 
n=1299 with 
MMSE≥24 
Median age 54.4 yrs. 
No Medication use 
HbA1c ≥6.5% 
FBG ≥126 mg/L 
OGTT ≥200 mg/L 
Composite score for global 
cognition from CERAD-
battery 
Increased odds of 
poor cognitive 
function 
None 
Tuligenga et al.  
2014 (27) 
UK 
Population-based 
n=5183 dementia-free 
Median age 54.4 yrs. 
FBG 6.1-7.0 
(non-fasting 
<7.0) mmol/L  
and 
OGTT <7.8 
(non-fasting 
7.8-11.1) 
mmol/L 
FBG ≥7.0 mmol/L 
OGTT ≥11.1 
mmol/L 
 
Composite from z-scores: 
Global score 
Memory 
Reasoning 
Phonemic fluency 
     Semantic fluency 
Diabetes had poor 
performance in 
reasoning. 
 
No association for 
prediabetes 
Age, sex, education, marital 
status, VRF, diet, CVDs, 
hypertension, respiratory 
disease, cholesterol, 
antidepressant, lipid-lowering 
drugs 
Köhler et al.  
2012 (26) 
Germany 
 
GP-based 
n=3327 dementia-free 
Aged ≥75  
No Self-report Single cognitive tests: 
• Immediate/delayed recall  
• Verbal fluency  
Poor performance 
in executive 
function 
Age, sex, education, living 
alone, CVDs, hypertension, 
depressive symptoms, 
medication 
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Vicario et al.  
2012 (28) 
Argentina 
 
Population-based  
n=1365 dementia-free  
Aged ≥18  
No FBG ≥126 mg/L MMSE (global cognition) 
Single cognitive tests: 
• Benton orientation 
questionnaire 
• Boston Naming test  
• Clock Drawing test  
• Alternating series test 
Poor performance 
in global cognition 
(MMSE and 
Benton) and 
executive function 
(clock and 
alternating series) 
None 
van den Berg et 
al. 
2010 (29) 
Netherlands 
 
Clinical-based  
case-control 
n=106 (68 diabetes) 
dementia-free  
Aged 56-80 
No Physician-report Composite from z-scores: 
Memory 
Attention/executive  
Abstract reasoning 
Visuo-constructional 
Speed 
Poor performance 
in  speed and 
attention/executiv
e function 
Age, sex, education, 
estimated IQ 
Arvanitakis et al. 
2010 (18) 
USA 
 
Population-based  
n=3350 dementia-free 
Aged 43-70 
No Self-report 
Medication use 
Composite from z-scores: 
Episodic memory 
Semantic memory 
Working memory 
Visuospatial 
Speed 
Poor performance 
in semantic 
memory 
Age, sex, education, race 
 
 
Yeung et al.  
2009 (32) 
Canada 
 
Population-based 
n=465 dementia-free 
Aged 53-90 
No Self-report 
Medication use 
Medical records 
MMSE (global cognition) 
Single cognitive tests: 
• Immediate/delayed recall; 
Story (episodic memory) 
• Vocabulary; Fact recall 
(semantic memory) 
• Opposite; Figure of speech; 
Similarities (verbal fluency) 
• Hayling; Brixton Spatial 
Anticipation; Stroop 
(executive function) 
• Five speed tests (speed) 
Poor performance 
in speed and 
executive function  
None 
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Ruis et al.  
2009 (19) 
Netherlands 
Case-control 
n=252 (183 diabetes) 
dementia-free 
Aged 50-70 
No Self-report 
Medication use 
FBG ≥7.1 
mmol/L 
RBG ≥11.1 
mmol/L 
OGGT ≥11.1 
mmol/L 
 
Composite from z-scores: 
Memory 
Attention/executive  
Abstract reasoning 
Visuo-construction 
Language comprehension 
Processing speed 
Poor performance 
in memory 
Age, sex, education, IQ 
Maggi et al.  
2009 (30) 
Italy 
Population-based  
n=3037 
Aged ≥65 
No Self-report 
Medication use 
Medical records 
FBG ≥140 mg/dl 
MMSE (global cognition) 
Single cognitive tests: 
• Story immediate/delayed 
recall (episodic memory) 
• Attentional matrix (attention) 
Poor performance 
in MMSE and 
attention among 
women but not 
men 
Age, sex, education, BMI, 
CVD, hypertension, 
parkinsonism, neuropathy, 
depressive symptoms  
Okereke et al.  
2008 (20) 
USA 
Population-based 
n=12233 
Aged ≥65 
No Self-report 
 
TICS (global cognition) 
Single cognitive tests: 
• Immediate/delayed recall; 
TICS-recall (memory) 
• Category fluency (verbal 
fluency) 
 
Composite from z-scores: 
Global cognition 
Memory 
Poor performance 
in TICS and 
memory among 
men and women 
Age, education, VRFs, high 
blood pressure, high 
cholesterol, physical activity, 
depression, (postmenopausal 
hormone use in women). 
Saczynski et al. 
2008 (31) 
Iceland 
Population-based 
n=1917 
Aged ≥65 
FBG 5.6-6.9 
mmol/L 
Self-report 
Medication use 
FBG ≥7.1 
mmol/L 
Composite from z-scores: 
Memory 
Executive function 
Processing speed 
Diabetes: poor 
performance in 
executive function 
and speed 
 
No association for 
prediabetes 
Age, sex, education, VRFs, 
hypertension,  APOE ε4, 
myocardial infarction, 
cholesterol, white matter 
lesions load, visual acuity, 
insulin level 
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van Harten et al. 
2007 (42) 
Netherlands 
Clinical-based  
case-control 
n=136 (92 diabetes) 
Aged ≥60 
No Medical records Composite from z-scores: 
Global cognition 
Executive function 
Mental speed 
Motor speed 
Poor performance 
in executive 
function and 
speed tasks 
Age, sex, education, 
hypertension 
Brands et al.  
2007 (21) 
Netherlands 
Clinical-based  
case-control 
n=174 (119 diabetes)  
Aged 56-78 
No Medical records Composite from z-score: 
Memory 
Attention/executive  
Abstract reasoning 
Visuo-construction 
Processing speed 
Poor performance 
in memory, 
attention/executiv
e function, speed 
 
Depression 
van den Berg et al. 
2006 (33) 
Netherlands 
Population-based 
n=596 
Aged 85-90 
No Medical records 
Medication use 
MMSE (global cognition) 
Single cognitive tests: 
• Immediate/delayed recall 
(memory) 
• Stroop test 
(attention/executive) 
• Letter Digit Coding (speed) 
Poor performance 
in speed and 
attention/executive  
Sex, education 
Debling et al.  
2006 (35) 
Germany 
Population-based 
n=740 
Aged ≥70 
No Self-reported 
Medication use 
TICS (global cognition) 
Immediate/delayed recall 
(memory) 
Poor TICS 
performance 
Age, sex, education, VRF, 
physical exercise,  depressive 
symptoms 
Arvanitakis et al. 
2006 (22) 
USA 
Population-based 
n=882 dementia-free 
Mean age 80 yrs.  
No Self-reported 
Medication use 
Composite from z-score: 
Episodic memory 
Semantic memory 
Working memory 
Perceptual speed 
Visuospatial ability 
Poor performance 
in semantic 
memory and 
speed 
Age, sex, education 
Kumari et al.  
2005 (38) 
UK 
Population-based 
n=5183 dementia-free  
Median age 54.4 yrs. 
No Self-reported 
FBG ≥7.0 mmol/L 
OGTT ≥11.1 
mmol/L 
Single cognitive tests: 
• Word free recall (memory) 
• Alice Heim 4 (reasoning) 
• Phonemic fluency 
• Semantic and semantivc 
fluency (verbal) 
• Mill Hill (language) 
Poor performance 
in reasoning and 
language 
Age, employment grade 
Prediabetes, diabetes, cognitive aging, and dementia 
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Kanaya et al.  
2004 (48) 
USA 
Population-based 
n=999 
Aged 42-89 
OGTT 140-199 
mg/dL 
Self-reported 
FBG ≥126 
mg/dL 
OGTT ≥200 mg/dL 
MMSE (global cognition) 
Single cognitive tests: 
• Verbal fluency  
• Trail Making Test-B 
(attention/executive) 
No association for 
diabetes or 
prediabetes 
Age, education, depressive 
symptoms,  APOE ε4 
(estrogens in women) 
Yaffe et al.  
2004 (41) 
Multicenter 
Population-based 
n=7027 women 
Aged >60 
FBG 6.1-7.0 
mmol/L 
Self-reported 
Medication use 
FBG ≥7.0 
mmol/L 
Single cognitive tests: 
• Word list recall (memory) 
• Word fluency (semantic 
memory) 
• Trail Making Test-A, B 
(attention/executive) 
Composite z-score for global 
cognition 
Pre- plus 
diabetes: 
poor performance 
in Trail A and 
recall task, and 
global cognition. 
 
 
Age, education, race, 
depression 
Hassing et al.  
2003 (23) 
Sweden 
Population-based 
n=338  
Aged 80-93 
No Medical records 
FBG ≥6.7 
mmol/L 
MMSE (global cognition) 
Single cognitive tests: 
• Prose recall, Thurstone’s 
Picture Memory, Memory-in-
Reality (episodic memory) 
• Information Task, Verbal 
Meaning test (semantic 
memory) 
• Digit Span test (short-term 
memory) 
• Symbol-Digit Substitution & 
Perceptual speed testa 
(speed) 
• Koh’s Block Design, Clock 
Test (visuo-spatial) 
• Figure Logic task (reasoning) 
Poor performance 
in all cognitive 
tests. 
 
None 
Nilsson et al.  
2002 (180) 
Sweden 
Population-based 
n=392 dementia-free 
Aged ≥75 
No Self-reported 
Medication use 
Inpatient registry 
RBG >6.0 mmol/L 
MMSE (global cognition) Poorer MMSE 
performance  
Age, sex, education, CVDs, 
hypertension 
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Wahlin et al.  
2002 (24) 
Sweden 
Population-based 
n=338 dementia-free 
Aged ≥75 
No Self-reported 
Medication use 
Inpatient registry 
RFBG >6.0 
mmol/L 
Single cognitive tests: 
• Episodic word recall 
(memory) 
• Verbal fluency  
Poorer 
performance in 
memory and letter 
fluency 
Age, sex, education, CVDs 
Asimakopoulou et 
al. 2002 (25) 
UK 
Clinical-based case-
control 
n=66 (33 diabetes)  
Aged ≥39 
No Self-reported 
Medical records 
Single cognitive tests: 
• DSST (speed)  
• Digit Span; Logical Memory 
A, B; Implicit memory 
(memory) 
• Trail Making Test-A, B 
(executive function)  
Poorer 
performance in 
tasks of episodic 
and working 
memory  
Age, premorbid IQ, BMI, 
depression 
Fontbonne et al. 
2001 (36) 
France 
Population-based 
n=961 with 
MMSE>26 
Aged 59-71 
FBG 6.1-7.0 
mmol/L 
 
Self-reported 
FBG ≥7.0 
mmol/L 
 
MMSE (global cognition) 
Single cognitive tests: 
• Immediate recall; Benton 
Visual Retention (memory) 
• Trail Making Test-B; PASAT 
(attention/executive) 
• Facial Recognition 
(visuospatial/attention) 
• Raven’s Matrices 
(Reasoning) 
• DSST; Finger Tapping 
(speed) 
Diabetes:  
Poorer 
performance in 
speed tasks. 
 
No association for 
prediabetes 
Age, sex, education 
Lindemann et al. 
2001 (39) 
USA 
Population-based 
n=883 dementia-free, 
aged ≥65 
FBG 6.1-7.0 
mmol/L 
OGTT 7.8-
11.1 mmol/L 
 
Medication use 
FBG ≥7.0 
mmol/L 
OGTT ≥11.1 
mmol/L 
 
 
MMSE  
Single cognitive tests: 
• Fuld Object Memory 
Evaluation (memory) 
• Digits forward 
(attention/memory) 
• Clock test (visuoconstruction) 
• Trail Making Test 
(executive function) 
No association for 
diabetes or 
prediabetes 
Age, sex, education, ethnicity, 
depression 
Prediabetes, diabetes, cognitive aging, and dementia 
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Cosway et al.  
2001 (34) 
Scotland 
Clinical-based case-
control 
n=76 (38 diabetes) 
Aged 40-75 
No Medical records 
HbA1c ≥6.5% 
Single cognitive tests: 
• Wechsler Memory Scale; 
Words immediate and 
delayed recall (memory) 
• Raven’s Matrices 
(reasoning) 
• Verbal fluency  
• Reaction time; Inspection 
time and Visual change 
detection (speed) 
No association. Age 
Grodstein et al. 
2001 (37) 
USA 
Population-based  
n=1374 women 
Aged 70-78 
No Self-reported 
Medical records 
Medication use 
TICS (global cognition) 
Single cognitive tests: 
• Boston naming test 
(memory) 
• Verbal fluency  
Poorer TICS 
performance  
Age, education, vitality index, 
blood pressure, BMI, use of 
vitamin E, antidepressant, 
postmenopausal hormones  
Sinlair et al.  
2000 (181) 
UK 
Population-based 
case-control 
n=789 (396 diabetes) 
dementia-free 
Aged ≥65 
No Medical records 
Medication use 
FBG ≥6.5 
mmol/L 
MMSE (global cognition) 
Clock test  
Poor performance 
in all tests 
Age, sex, school-leaving age, 
occupation, VRFs 
Ryan et al.  
2000 (40) 
USA 
Population-based 
case-control 
n=100 (50 diabetes) 
Aged 34-65 
No Medical records 
 
Composite from factorial 
analysis: 
Learning 
Memory for stories 
Problem-solving 
Psychomotor speed 
No association Age, sex, race, Information 
task 
Abbreviations: APOE ɛ4, apolipoprotein E gene-ɛ4 allele; BMI, body mass index; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; CVD, cardio- and 
cerebrovascular disorders; DSST, digit symbol substitution; FBG, fasting blood glucose; GP, general practitioner; HbA1c, glycated hemoglobin; IQ, intelligence quotient; 
mmol/L, millimoles per liter; MMSE, Mini-Mental State Examination; OGTT, oral glucose tolerance test; PASAT, Paced Auditory Serial Addition Test; RBG, random 
blood glucose; TICS, Telephone Interview for Cognitive Status; VRF, vascular risk factors.
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11.2 SUMMARY OF THE LONGITUDINAL STUDIES ON THE RELATIONSHIP BETWEEN PRE/DIABETES AND COGNITIVE DECLINE 
Reference Study population Follow-up Prediabetes Diabetes Cognitive domains Results Covariates 
Palta 2017 
USA (56) 
Population-based 
n=3027 dementia-free 
Aged 72-96 
2 waves 
7 years 
No Self-reported 
Medication use 
Composite from z-scores: 
Memory 
Attention/speed 
Executive function 
Visuospatial 
Language 
Faster decline in 
attention/speed 
 
Age, sex, education, 
ethnicity, smoking, 
CVDs, hypertension, 
depressive 
symptoms 
Demakakos 
2017 
UK (45) 
Population-based 
n=10524 dementia-free 
Aged ≥50 
6 waves 
10 years 
No Self-reported 
 
Single cognitive tests: 
• Immediate/delay recall 
(memory) 
• Verbal fluency 
No association Age, sex, education, 
marital status, 
occupation, VRF, 
CVDs  
Sano 2017 
USA (57) 
Population-based 
n=7663 dementia-free 
Aged ≥65 
Mean 5 yrs. No Medical history Composite from z-scores: 
Global 
Memory 
Attention/working 
Language 
Executive function 
Faster decline in 
global and 
executive function 
Age, gender, 
ethnicity, site, 
education, VRF, 
hypertension, stroke, 
depression 
 
Rajan 2016 
USA (43) 
Population-based 
n=7740  
Aged ≥65 
4 waves 
Mean 9 yrs. 
No Medication use 
Medicare registry 
Composite score for 
global cognition  
Faster decline Age, sex, education, 
BMI, hypertension, 
stroke, statin and 
antihypertensive use 
Mayeda 2015 
USA (44) 
 
Population-based 
n=1634 dementia-free 
Aged ≥60 
8 waves 
8 years 
No Self-reported 
Medication use 
FBG ≥126 mg/L 
Short-MMSE (global) Faster decline  Age, sex, education, 
abdominal obesity, 
CVDs, hypertension, 
depressive 
symptoms 
Rawling 2014  
USA (52) 
 
Population-based 
n=13351  
Aged 48-67 
3 waves 
20 years 
No Self-reported 
Medication use 
HbA1c ≥6.5% 
Composite from z-scores: 
Global cognition 
Memory 
Executive function 
Speed 
Faster decline in 
global cognition, 
executive function,  
speed 
Age, sex, education, 
center, VRF, CVDs, 
hypertension, APOE 
ε4 
Prediabetes, diabetes, cognitive aging, and dementia 
72 
Mayeda 2014  
USA (51) 
 
Population-based 
n=1886 
Aged 48-70 
4 waves 
14 years 
No Self-reported 
Medication use 
FBG ≥7.0 mmol/L 
RBG ≥11.1 
mmol/L 
Single cognitive tests: 
• Delayed recall 
(memory) 
• Letter fluency (verbal) 
• DSST (speed) 
Faster decline in 
verbal fluency and 
speed 
 
Age, sex, education, 
waist circumference, 
hypertension 
Tuligenga 2014 
UK (27) 
 
Population-based 
n=5183 dementia-free 
Median age 54 yrs. 
3 waves 
10 years 
FBG 6.1-7.0 
(non-FBG 
<7.0) mmol/L 
and 
OGTT <7.8 
(non-fasting 
7.8-11.1) 
mmol/L 
 
FBG ≥7.0 mmol/L 
OGTT ≥11.1 
mmol/L 
Composite from z-scores: 
Global cognition 
Memory 
Reasoning 
Phonemic fluency 
Semantic fluency 
Faster decline in 
global cognition, 
memory, reasoning 
 
No association for 
prediabetes 
Age, sex, education, 
marital status, VRF, 
diet, CVDs, 
hypertension, 
respiratory disease, 
cholesterol, 
antidepressant, lipid-
lowering drugs 
Samaras 2014 
Australia (49) 
 
Population-based 
n=880 dementia-free 
Aged 70-90 
2 waves 
2 years 
FBG 5.6-6.9 
mmol/L 
Self-reported 
Medication use 
FBG ≥7.0 mmol/L 
Composite from z-scores: 
Global cognition 
Memory 
Executive function 
Visuospatial 
Language 
Speed 
Faster decline in 
executive function 
 
No association for 
prediabetes 
Age, sex, education, 
non-English 
speakers, VRF, 
antihypertensive 
medications, 
depressive 
symptoms, APOE ε4 
Spauwen 2013 
Netherlands 
(53) 
 
Population-based 
n=1823 dementia-free  
Aged ≥40 
3 waves 
12 years 
No Self-reported 
Medication use 
MMSE (global) 
Single cognitive tests: 
• Visual verbal learning 
(memory) 
• Concept Shifting 
(executive function) 
• Letter Digit Substitution 
(speed) 
Faster decline in 
memory, executive 
function, and speed 
Age, sex, education, 
VRF, CVDs, 
hypertension, 
depressive 
symptoms, APOE ε4 
Köhler 2012  
Germany (26) 
 
GP-based 
n=3327 dementia-free 
Aged ≥75 
4 waves 
4.5 years 
No Self-report Single cognitive tests: 
• Immediate/delayed 
recall  
• Verbal fluency 
No association  Age, sex, education, 
living alone, CVDs, 
hypertension, 
depressive symptoms, 
medication use 
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Yaffe 2012 
USA (182) 
 
Population-based 
n=3069,  
Aged 70-79 
4/5 waves 
9 years 
No Self-report 
Medication use 
FBG ≥126 mg/L 
OGTT ≥200 mg/dL 
Short-MMSE (global) 
DSST (speed) 
Faster global 
decline 
Age, sex, education, 
race 
Wessels 2011 
USA (54) 
 
Population-based 
n=1702 dementia-free  
Aged ≥65 
6 waves 
15 years 
No Self-report 
Medication use 
Community Screening 
Interview for Dementia 
Faster decline Age, sex, education, 
dementia family 
history, CVDs, 
hypertension, 
depression 
Nooyens 2010 
Netherlands 
(55) 
 
Population-based  
n=3350,  
aged 43-70 
2 waves 
5 years 
No Self-reported  
GP-reported 
RBG ≥11.1 
mmol/L 
Composite from z-scores: 
Global cognition  
Memory 
Cognitive flexibility 
Speed 
Faster decline in 
global cognition, 
memory, flexibility 
(in 60+ yrs.) 
Age, sex, education, 
physical activity, 
VRF, metabolic 
syndrome factors, 
myocardial infarction 
van den Berg 
2010 
Netherlands 
(29) 
 
Clinical-based  
case-control 
n=106 (68 diabetes) 
dementia-free  
Aged 56-80 
2 waves 
4 years 
No  Physician-report Composite from z-scores: 
• Memory 
• Attention/executive  
• Abstract reasoning 
• Visuo-constructional 
• Speed 
No association Age, sex, education, 
estimated IQ 
Fischer 2009  
Canada (46) 
 
Population-based 
n=465 dementia-free  
Aged 53-90 
2 waves 
3 years 
No Self-report 
Medication use 
Composite from z-scores: 
• Semantic memory 
• Fluency 
• Semantic speed 
• Speed/executive function 
No association Systolic blood 
pressure 
Maggi 2009 
Italy (30) 
 
Population-based 
n=3037 dementia-free  
Aged ≥65 
3 waves 
8 years 
No Self-report 
Medication use 
Medical records 
FBG ≥140 mg/dl 
MMSE (global cognition) 
Single cognitive tests: 
• Immediate/delayed 
recall (memory) 
• Attentional matrix  
Greater memory 
decline (only in 
women) 
Age, education 
Prediabetes, diabetes, cognitive aging, and dementia 
74 
Okereke 2008  
USA (20)  
Population-based 
n=12 233 dementia-
free  
Aged ≥65 
PHS-II: 
2 waves 
2 years 
 
WHS: 
3 waves 
4 years 
No Self-report 
 
TICS (global cognition) 
Single cognitive tests: 
• Immediate and delayed 
recall; TICS-recall 
(memory) 
• Category fluency  
 
Composite from z-scores: 
Global cognition 
Memory 
Greater decline in 
global cognition and 
memory 
Age, education, 
VRF, blood 
pressure, physical 
activity, cholesterol, 
depression, 
postmenopausal 
hormone use 
van den Berg  
2006  
Netherlands 
(33) 
Population-based 
n=596 
Aged 85-90 
5 waves 
5 year 
No Medical records 
Medication use 
MMSE (global cognition) 
Single cognitive tests: 
• Immediate/delayed  
recall (memory) 
• Stroop test 
(attention/executive) 
• Letter Digit Coding 
(speed) 
No association Sex, education 
Arvanitakis 
2004  
USA (58) 
 
Population-based 
n=824 dementia-free 
Aged ≥55 
5.5 
evaluations 
1-9 years 
No Self-reported 
Medication use 
Composite from factorial 
analysis: 
Episodic memory 
Semantic memory 
Working memory 
Visuospatial ability 
Perceptual speed 
Faster decline in 
speed 
Age, sex, education, 
stroke 
Kanaya 2004  
USA (48) 
 
Population-based 
n=999  
Aged 42-89 
2 waves 
4 years 
OGTT 140-
199 mg/dL 
Self-reported 
FBG ≥126 mg/dL 
OGTT ≥200 mg/dL 
MMSE (Global cognition) 
Single cognitive tests: 
• Verbal fluency  
• Trail Making Test-B 
(executive) 
Greater decline in 
verbal fluency 
 
No association for 
prediabetes 
Age, education, 
depressive 
symptoms, baseline 
cognition, APOE ε4, 
estrogens 
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Hassing 2004  
Sweden (50) 
 
Population-based 
n 274 dementia-free 
Aged ≥80 
4 waves 
6 years 
No Medical records 
FBG ≥6.7 mmol/L 
MMSE (Global cognition) 
Single cognitive tests: 
• Prose recall; Thurstone; 
Memory-in-reality 
(episodic memory) 
• Digit span (short-term 
memory) 
• Information; Verbal 
meaning (semantic 
memory) 
• Block design 
(visuospatial) 
• Digit Symbol 
Substitution; Figure 
similarity (speed) 
Faster decline in 
MMSE, semantic 
memory, 
visuospatial, speed 
Age, sex, education 
Yaffe 2004  
USA, Canada 
(41) 
 
Population-based 
n=7027 women 
Aged >60 
2 waves 
4 years 
FBG 6.1-7.0 
mmol/L 
Self-reported 
Medication use 
FBG ≥7.0 mmol/L 
Single cognitive tests: 
• Word list recall (episodic 
memory) 
• Word fluency (verbal) 
• Trail Making Test-A, B 
(attention/executive) 
Composite z-score for 
global cognition 
Faster decline in 
semantic memory, 
attention/executive 
 
No association for 
prediabetes 
Age, education, 
race, depression 
Wu 2003 
USA (47) 
 
Population-based 
n=1789  
Aged ≥60 
2 waves 
2 years 
No Self-reported 
Medication use 
FBG ≥126 mg/dL 
Short-MMSE (global) 
Immediate/delayed recall 
(episodic memory) 
No association Age, sex, education, 
acculturation, 
hypertension, 
depressive symptoms 
Stewart 2003  
UK (183) 
 
Population-based 
n=290  
Aged 55-75 
2 waves 
3 years 
No Self-reported Single cognitive tests: 
• Orientation 
• Immediate/delayed  
recall; recognition 
(memory) 
• Trail Making Test-A 
(speed/attention) 
Increased odds of 
global decline 
Age, sex, education, 
occupation, exercise, 
hypertension 
Prediabetes, diabetes, cognitive aging, and dementia 
76 
Knopman 2001 
USA (184) 
 
Population-based 
n=10 936 
Aged 47-70 
2 waves 
6 years 
No Self-reported 
Medication use 
FBG ≥126 mg/dL 
no-FBG ≥200 
mg/dL 
Single cognitive tests: 
• Delayed recall (memory) 
• DSST (speed) 
• Word fluency (verbal) 
Greater decline in 
speed and verbal 
Age, sex, education, 
centre, CNS 
medications use at 
visit 2 
Fontbonne  
2001  
France (36) 
 
Population-based 
n=961 with MMSE>26 
Aged 59-71 
3 waves 
4 years 
FBG 6.1-7.0 
mmol/L 
 
Self-reported 
FBG ≥7.0 mmol/L 
 
MMSE (global cognition) 
Single cognitive tests: 
• Immediate recall; 
Benton Visual 
Retention (memory) 
• Trail Making Test-B; 
PASAT 
(attention/executive) 
• Facial Recognition 
(visuospatial/attention) 
• Raven’s Matrices 
(Reasoning) 
• DSST; Finger Tapping 
(speed) 
No association for 
diabetes or 
prediabetes 
Age, sex, education 
Gregg 2000 
USA (185) 
 
Population-based 
n=9679 women  
Aged ≥65 
3 waves 
6 years 
 Self-reported 
Insulin use 
MMSE (global cognition) 
Single cognitive tests: 
• DSST (speed) 
• Trail Making Test-B 
(executive) 
Greater decline in 
speed and 
executive function 
Age, education, 
VRF, hypertension, 
stroke, visual 
impairment, 
estrogens use, 
depression 
Abbreviations: APOE ɛ4, apolipoprotein E gene-ɛ4 allele; BMI, body mass index; CNS, central nervous system; CVD, cardio- and cerebrovascular disorders; DSST, digit 
symbol substitution; FBG, fasting blood glucose; GP, general practitioner; HbA1c, glycated hemoglobin; IQ, intelligence quotient; mmol/L, millimoles per liter; MMSE, 
Mini-Mental State Examination; OGTT, oral glucose tolerance test; PASAT, Paced Auditory Serial Addition Test; RBG, random blood glucose; TICS, Telephone 
Interview for Cognitive Status; VRF, vascular risk factors. 
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11.3 SUMMARY OF THE LONGITUDINAL STUDIES ON THE ASSOCIATION BETWEEN PRE/DIABETES AND BRAIN MRI MARKERS 
Reference Study population Follow-up Prediabetes Diabetes MRI markers Results (longitudinal) Covariates 
Shaw 2017 
Australia (80) 
Population-based 
n=322 
Aged 60-66 
3 waves  
12 years 
FBG 6.1-6.9 
mmol/L 
Self-reported 
medication use 
FBG ≥7.0 mmol/L 
1.5 Tesla 
Cortical thickness 
(CT) 
High FBG 
(pre/diabetes) was 
associated with faster 
annual decline in CT 
ICV, age, sex, 
education, BMI, 
hypertension, APOE ε4, 
depression 
Reitz 2016 
USA (83) 
Population-based 
n=618 dementia-free 
Aged ≥65 
2 waves  
4 years 
HbA1c 5.7-6.4% Self-reported 
Medication use 
HbA1C ≥6.5% 
1.5 Tesla 
GMV, WMV, HV, 
WMHV, Infarcts 
No additional 
changes 
ICV, age, sex, race, 
education, smoking, 
BMI, hypertension, 
HDL, APOE ε4 
Kooistra 2013 
Netherlands 
(81) 
Clinical-based 
n=663 with 
atherosclerotic dis. 
Aged 18-79 
2 waves 
3.9 years 
No Self-reported  
Medication use 
RBG ≥11.1 mmol/l 
1.5 Tesla 
TBV, GMV, WMV, 
CSFV, VV, white 
matter lesions, 
Infarcts 
Faster VV increase, 
Higher risk of infarcts 
Age, sex, smoking, 
alcohol, BMI, SBP, 
DBP, hyperlipidemia, 
cerebrovascular 
disease 
Espeland 2013 
USA (multisite) 
(84) 
Clinical trial-based 
n= 1366 women 
aged 56-80 
2 waves  
4.7 years 
No Self-reported 
Medication use 
FBG >126 mg/dL  
(when available) 
1.5 Tesla 
GMV, WMV, VV, 
CSFV, region of 
interest volume 
No additional 
changes 
 
 
ICV, age, center, 
treatment assignment, 
time between scans, 
baseline volume 
van Elderen 
2010 
Netherlands 
(82) 
Clinical trial-based 
n=527 dementia-free 
with atherosclerotic dis. 
Aged 70-82 
2 waves 
3 years 
No History of diabetes 
FBG ≥7.0 mmol/L 
1.5 Tesla 
TBV, WMHV 
(periventricular & 
deep), Infarcts 
Faster decrease TBV  
 
 
Age, sex, hypertension, 
pravastatin treatment, 
and baseline TBV 
(longitudinal) 
de Bresser 
2010 
Netherlands 
(85) 
Clinical-based 
n=83  
aged 56 to 80 
2 waves  
4 years 
No GP-based 1.5 Tesla 
TBV, CSFV, lateral 
VV,  WMHV 
Greater lateral VV 
increase  
ICV, age, sex 
Abbreviations: APOE ɛ4, apolipoprotein E gene-ɛ4 allele; BMI, body mass index; CSFV; cerebrospinal fluid volume; CT, cortical thickness; DBP, diastolic blood 
pressure; FBG, fasting blood glucose; GMV, grey matter volume; GP, general practitioner; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; HV, hippocampal 
volume; ICV, intracranial volume; mmol/L, millimoles per liter; RBG, random blood glucose; SBP, systolic blood pressure; TBTV, total brain tissue volume; VV, 
ventricular volume; WMHV, white matter hyperintensities volume; WMV, white matter volume. 
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